East Tennessee State University

Digital Commons @ East
Tennessee State University
Electronic Theses and Dissertations

Student Works

12-2007

1, Structural and Functional Studies of Human
Replication Protein A; 2 DNA Damage Responses
and DNA Repair Defects in Laminopathy-Based
Premature Aging.
Yiyong Liu
East Tennessee State University

Follow this and additional works at: https://dc.etsu.edu/etd
Part of the Molecular Genetics Commons
Recommended Citation
Liu, Yiyong, "1, Structural and Functional Studies of Human Replication Protein A; 2 DNA Damage Responses and DNA Repair
Defects in Laminopathy-Based Premature Aging." (2007). Electronic Theses and Dissertations. Paper 2062. https://dc.etsu.edu/etd/
2062

This Dissertation - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State
University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East
Tennessee State University. For more information, please contact digilib@etsu.edu.

1, Structural and Functional Studies of Human Replication Protein A; 2, DNA Damage
Responses and DNA Repair Defects in Laminopathy-Based Premature Aging

_____________________

A dissertation
presented to
the faculty of the Department of Biochemistry and Molecular Biology
East Tennessee State University

In partial fulfillment
of the requirements for the degree
Doctorate of Philosophy in Biomedical Sciences

_____________________
by
Yiyong Liu
December, 2006
_____________________

Yue Zou, Ph.D. Chair
David A. Johnson, Ph.D.
John J. Laffan, Ph.D.
Peter J. Rice, Pharm.D., Ph.D.
Douglas P. Thewke, Ph.D.

Keywords: DNA Repair, DNA Damage Responses, Replication Protein A, Laminopathy

ABSTRACT

1, Structural and Functional Studies of Human Replication Protein A; 2, DNA Damage
Responses and DNA Repair Defects in Laminopathy-Based Premature Aging
by
Yiyong Liu

The genome of mammalian cells is under constant attack from DNA-damaging agents. To
maintain genomic integrity, cells activate an array of pathways primarily consisting of DNA
repair and DNA damage checkpoints. Human replication protein A (RPA), a single-stranded
DNA (ssDNA) binding protein, is essential for almost all DNA metabolic pathways. However,
the role of RPA in nucleotide excision repair (NER), a DNA repair pathway for removing bulky
DNA lesions, remains elusive. In this study, the binding of RPA to a battery of well-defined
ssDNA substrates has been systematically examined using fluorescence spectroscopy. The
results showed that RPA has a lower binding affinity for damaged ssDNA than for non-damaged
ssDNA, and there was no direct contact between RPA residues and the lesion itself. These
findings will help define the roles of RPA in DNA damage recognition in NER. In cells, RPA
undergoes hyperphosphorylation in the N-terminus of RPA32 subunit after DNA damage. In this
study, the hyperphosphorylation-induced conformational changes of RPA have been probed
using mass spectrometry-based protein foot-printing, fluorescence spectroscopy, and limited
proteolysis. The data show that upon hyperphosphorylation RPA undergoes a subtle structural
change involving its DNA-binding domain B (DBD-B), reducing its affinity for short ssDNA.
These results suggest that hyperphosphorylation may modulate RPA functions by altering DBD-
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B-mediated RPA-DNA/protein interactions. Cellular accumulation of DNA damage has been
widely implicated in premature aging. In Hutchinson-Gilford progeria syndrome (HGPS) and
restrictive dermopathy (RD), premature aging is caused by defective maturation of lamin A and
linked to accumulation of DNA double-strand breaks (DSBs). However, how lamin A
dysfunction leads to genome instability and premature aging is not understood. Here evidence
showed that in HGPS and RD fibroblasts DNA damage checkpoints are persistently activated
and recruitment of repair factors to DSBs was impaired. Strikingly, xeroderma pigmentosum
group A (XPA), a unique NER protein, formed foci and colocalized with the unrepairable DSBs
in the patient cells. RNAi knockdown of XPA in HGPS cells significantly restored DSB repair.
These results indicate that XPA dysfunction may play an important role in accumulating DSBs in
HGPS, implicating a potential strategy for treatment of these premature aging diseases.
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CHAPTER 1

INTRODUCTION

DNA Damage and Cellular Responses
The genomic integrity of mammalian cells is constantly challenged by endogenous
insults of metabolic byproducts such as reactive oxygen radicals as well as environmental factors
such as chemical agents and ultraviolet (UV) radiation. Limits to the fidelity of DNA metabolism
including replication, recombination, and repair also promote genomic instability. Damage to
DNA elicits four types of cellular pathways, including DNA repair, DNA damage checkpoints,
transcriptional response, and apoptosis (Figure 1-1), to either repair the DNA or eliminate cells
with heavy damage (Sancar et al., 2004; Zhou and Elledge, 2000). Failure to correctly cope with
DNA damage may cause accumulation of genomic rearrangements that promote tumorigenesis
(Kolodner et al., 2002). It has been estimated that 80-90% of human cancers may partially result
from DNA damage (Doll and Peto, 1981).

DNA damage

Damage sensors

DNA repair

Transcriptional
response

DNA damage
checkpoints

Apoptosis

Figure 1-1. Four DNA damage response reactions in mammalian cells
Source: adapted from Sancar et al., 2004.
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DNA can be damaged in a variety of ways, including base damage (reduced, oxidized, or
fragmented bases), DNA backbone damage (abasic sites and single- or double-strand DNA
breaks), and cross-links (DNA-protein cross-links and interstrand or intrastrand cross-links).
There are six different types of DNA repair pathways including direct repair, base excision repair
(BER), mismatch repair (MMR), nucleotide excision repair (NER), double-strand break (DSB)
repair, and repair of interstrand cross-links. All these repair pathways have more than one
subpathway to recognize and remove a specific type of DNA damage. Because my doctoral
research focuses on NER and DSB repair, these two pathways will be introduced as follows.

Nucleotide Excision Repair (NER)
NER is the major mechanism for removal of a variety of structurally and chemically
unrelated bulky DNA lesions such as chemical adducts and the dimerized pyrimidine bases
induced by UV radiation. Defects in NER cause diseases such as xeroderma pigmentosum (XP),
Cockayne Syndrome (CS), and trichothiodystrophy (TTD) (Bootsma, 2002; Thoma and
Vasquez, 2003). There are two major NER subpathways: global genomic repair (GGR)
eliminates lesions from the entire genome, and transcription coupled repair (TCR) efficiently
removes lesions from the transcribed strand of active genes. Both subpathways follow the same
basic repair steps and require more than 25 proteins for DNA damage recognition, dual-incision,
excision, repair synthesis, and ligation (Thoma and Vasquez, 2003). As depicted in Figure 1-2
(page 17), in GGR, DNA damage-induced helical distortion is recognized by the XPC-hHR23B
(xeroderma pigmentosum group C-human homolog of RAD23B) complex, followed by
recruitment of transcription factor IIH (TFIIH). Xeroderma pigmentosum group A (XPA, a
metalloprotein) and replication protein A (RPA, a eukaryotic single-stranded DNA binding
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protein) arrive sequentially at the damage site and function in verifying the presence of DNA
lesions. But how this verifying process is carried out and the exact spatial arrangement of the
recognition factors at the damage site remain unknown. Endonuclease xeroderma pigmentosum
group G (XPG) and the xeroderma pigmentosum group F-excision-repair cross-complementing
group 1 (XPF–ERCC1) complex are responsible for the 3' and 5' DNA incisions, respectively.
Binding of XPG induces the release of XPC–hHR23B, whereas XPF–ERCC1 triggers excision
of the damaged DNA and the release of XPA and TFIIH. Subsequently, the newly formed gap in
the DNA is filled by DNA polymerase δ/ε, replication factor C (RFC), proliferating cell nuclear
antigen (PCNA), RPA and DNA ligase I (Park and Choi, 2006).

Double Strand Break (DSB) Repair
Among the various forms of DNA damage that are inflicted by mutagens, DSB probably
is the most dangerous lesion. DSBs can be caused by ionizing radiation, radio-mimetic
chemicals, reactive oxygen species (ROS), and mechanical stress on chromosomes (Jackson,
2002). DSBs can also be the result of normal V(D)J recombination or abnormal replication fork
arrest and collapse (Jackson, 2002; Sancar et al., 2004). Defects in DSB repair result in genomic
instability and apoptosis at the cellular level, and lead to increased predisposition to cancer in
animal models and in people. DSBs are repaired either by homologous recombination (HR) or
nonhomologous end-joining (NHEJ) mechanisms (Figure 1-3, page 18).
HR is an accurate repair process that is carried out by the Rad52 epistasis group. The
Mre11/Rad50/Xrs2 complex in budding yeast or the Mre11/Rad50/Nbs1 (MRN) complex in
mammals resects the 5’ ends of the DSB to generate 3’ ssDNA overhangs. Rad51, RPA,
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Figure 1-2. Scheme of the global genomic repair (GGR) pathway
The DNA damage such as UV-induced dimerized pyrimidines bases is recognized by the
xeroderma pigmentosum protein C-human homolog of RAD23B (XPC-hHR23B) complex
together with damage recognition factors xeroderma pigmentosum group A (XPA), replication
protein A (RPA) and transcription factor IIH (TFIIH). The damage site is then unwound by ~25
bp driven by ATR hydrolysis. The sequentially recruited endonucleases xeroderma pigmentosum
group G (XPG) and xeroderma pigmentosum group F-excision-repair cross-complementing
group 1 (XPF-ERCC1) complex are responsible for the 3’ and 5’ incisions, respectively. DNA
polymerase δ/ε, replication factor C (RFC), proliferating cell nuclear antigen (PCNA), RPA and
DNA ligase I fill the formed gap.
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Homologous recombination

Nonhomologous end-joining

Figure 1-3. Schematic representation of DSB repair pathways
DSBs are repaired by either homologous recombination or nonhomologous end-joining. Source:
adapted from Jackson, 2002.
Rad52 and Rad54 bind the resulting 3’ ssDNA strands and form an α helical nucleoprotein
filament that facilitates the migration of the damaged DNA strand into the homologous doublestrand DNA partner. DNA polymerase then extends the 3′ ends of the damaged DNA and DNA
ligase 1 ligates the ends, creating double Holiday junctions. After branch migration, the Holiday
junctions are then cleaved and ligated (Binz et al., 2004; Jackson, 2002).
NHEJ rejoins the two broken ends directly. It generally leads to small deletions of DNA
sequence. The first step of NHEJ is the binding of Ku 70/80 heterodimer to the double-stranded
ends of the DSB. Ku then recruits the kinase DNA-dependent protein kinase catalytic subunit
(DNA-PKcs). Some DSBs require processing by the Mrell/Rad50/Nbs1 (MRN) complex before
ligation. Processing can also be carried out by other proteins including the Artemis complex (in
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mammals) or Rad57 (yeast)/FEN-1 (mammals). The DNA-PK complex then recruits DNA ligase
IV and x-ray repair cross-complementing protein 4 (XRCC4), and phosphorylates XRCC4. This
is followed by DNA polymerization and ligation (Binz et al., 2004; Jackson, 2002).

DNA Damage Checkpoints
In addition to the repair of DNA damage in response to genotoxic insults, cells also
launch checkpoints to attenuate cell cycle progression and arrest replication, therefore preventing
DNA lesions from being converted to inheritable mutations (Li and Zou, 2005; Sancar et al.,
2004; Zhou and Elledge, 2000). The DNA damage checkpoint conceptually has four
components: sensors, mediator, signal transducers, and effectors (Figure 1-4, page 20) (Sancar et
al., 2004). Two protein kinases of the phosphoinositide 3-kinase-like kinase (PIKK) family,
ATM and ATR, and the Rad9-Rad1-Hus1/Rad17-Rfc2-5 checkpoint complex play the central
roles in initiating the checkpoints (Abraham, 2001; Li and Zou, 2005). ATM is activated
primarily in response to DNA double-strand breaks (DSBs) (Shiloh, 2003), whereas ATR is
activated by a broad array of DNA damage and replication interference (Abraham, 2001; Li and
Zou, 2005). Upon activation, with the aid of mediator such as claspin, BRCA1, 53BP, or MDC1,
ATM and ATR phosphorylate two major signal-transducing kinases Chk1 and Chk2, which in
turn regulate downstream targets, such as Cdc25A, Cdc25C, and p53, to control cell cycle
progression and DNA synthesis (Li and Zou, 2005; Sancar et al., 2004).

Replication Protein A (RPA) and Hyperphosphorylation
RPA is a heterotrimer consisting of RPA70, RPA32, and RPA14, named after their
molecular masses of 70, 32, and 14 kDa, respectively. RPA was originally defined as a
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Figure 1-4. Components of the DNA damage checkpoints in human cells
The signal of DNA damage is transduced from sensors to transducers with the aid of mediators.
The transducers activate or inactivate effectors to inhibit the G1/S transition, S-phase
progression, or the G2/M transition. Source: from Sancar et al., 2004.

eukaryotic single-stranded DNA binding protein essential for the in vitro replication of simian
virus 40 (SV40) DNA. Subsequent extensive studies revealed that RPA is required for almost all
cellular DNA metabolism such as DNA replication, recombination, DNA damage checkpoints,
and all major types of DNA repair including nucleotide excision, base excision, mismatch, and
double-strand break repairs. RPA participates in such diverse pathways through its ability to
interact with DNA and numerous proteins involved in these processes (Zou et al., 2006).
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RPA Structure and Interactions with ssDNA
Structurally, the heterotrimer RPA contains four DNA binding domains (DBDs) (Figure
1-5). The DBD is built around a central OB-fold (oligo-saccharide/oligonucleotide binding fold)
(Bochkarev et al., 1999; Bochkarev et al., 1997; Bochkareva et al., 2001; Bochkareva et al.,
2002; Jacobs et al., 1999), which consists of five β-strands in a Greek-key β-barrel and is found
in many single-stranded DNA-binding proteins (Murzin, 1993). RPA70 can be divided into 4

RPA32N
DBD-D

CTD

RPA32

NTD
RPA14

RPA70

DBD-A

DBD-B

DBD-C

Figure 1-5. Schematic representation of RPA structures
The four DBDs (DNA binding domains) are presented as boxes. NTD stands for the N-terminal
domain of RPA70, and CTD for the C-terminal domain of RPA32.

distinguishable regions, the N-terminal domain (RPA70N), DBD-A, -B, and –C, each having one
OB-fold (Bochkarev et al., 1997; Brill and Bastin-Shanower, 1998; Iftode et al., 1999; Jacobs et
al., 1999; Wold, 1997). The tandem DBD-A and DBD-B harbor the major ssDNA binding
activity of RPA trimer (Arunkumar et al., 2003; Bastin-Shanower and Brill, 2001; Iftode et al.,
1999; Wold, 1997). RPA32 consists of three domains, including an unstructured N-terminal
phosphorylation domain (RPA32N), a central DNA-binding domain (DBD-D), and a C-terminal
domain (RPA32C) largely involved in protein-protein interactions (Bochkarev et al., 1999;
Bochkareva et al., 1998; Mer et al., 2000). RPA14 has a single OB-fold referred as DBD-E,
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which is structurally important for the formation of RPA trimerization core (Bochkarev et al.,
1999; Bochkareva et al., 2002), but no DNA binding activity was found for this domain.
The binding of RPA to ssDNA has been suggested to occur through a multi-step pathway
(Bochkareva et al., 2002; Iftode et al., 1999). The binding is initiated by an interaction of the
DBD-AB domains with a length of 8–10 nucleotides (nt) of the ssDNA (Bochkareva et al.,
2002). Then, a significant conformational change of the protein allows ssDNA binding between
13 and 22 nt with the DBD-C domain additionally involved (Bastin-Shanower and Brill, 2001;
Kolpashchikov et al., 1999). Finally, co-operative binding of RPA with all the four DBDs
occurs, which involves a region of 30 nt (Bochkareva et al., 2002). It is now generally accepted
that RPA needs an occluded size of approximately 30 nt for a minimum full and high-affinity
binding (Blackwell and Borowiec, 1994; Iftode et al., 1999; Kim et al., 1992; Wold, 1997).

RPA Hyperphoshporylation
It has been well reported that the unstructured N-terminal domain (residues 1-42) of
RPA32 (RPA32N) becomes phosphorylated during the normal cell cycle (Din et al., 1990; Dutta
and Stillman, 1992; Oakley et al., 2003) and hyperphosphorylated in response to DNA damage
(Binz et al., 2004; Block et al., 2004; Cruet-Hennequart et al., 2006; Liu and Weaver, 1993;
Sakasai et al., 2006; Zernik-Kobak et al., 1997). There are nine serines/threonines located in
RPA32N. It remains unknown how many and which of these sites are concurrently
phosphorylated on a single RPA molecule upon DNA damage. Phospho-peptide mapping has
shown that at least five sites of RPA32N including Thr-21, Ser-23, Ser-29, Ser-33, and either
Ser-11, -12, or -13, and probably two additional sites, Ser-4 and Ser-8, can be phosphorylated in
UV-irradiated HeLa cells (Niu et al., 1997; Nuss et al., 2005; Zernik-Kobak et al., 1997). The
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DNA damage-induced hyperphosphorylation of RPA32 is believed to be carried out by PI-3
kinases DNA-PK, ATM, and ATR (Barr et al., 2003; Binz et al., 2004; Block et al., 2004; Brush
et al., 1994; Cruet-Hennequart et al., 2006; Iftode et al., 1999; Liu et al., 2006a; Pan et al., 1994;
Sakasai et al., 2006; Shao et al., 1999). But the relative contribution of these kinases to RPA
hyperphosphorylation and the potential different roles of the hyperphosphorylation by these
kinases have not been defined.
Besides phosphorylatable sites in RPA32N, efficient phosphorylation of Thr-98 in DBDD of RPA32 has been recently demonstrated by Nuss et al. (Nuss et al., 2005). In addition, like
yeast RPA70 that can be phoshporylated (Brush et al., 1996; Clifford et al., 2004; Kim and Brill,
2003), phoshporylation of human RPA70 also has been detected in vitro and in vivo (Liu et al.,
2006a; Nuss et al., 2005). There are no reports of phosphorylation of RPA14.
RPA is extensively involved in many DNA metabolic pathways by interacting with DNA
and/or a large variety of proteins. Although how hyperphosphorylation alters the activities of
RPA in these cellular reactions remains largely unknown, several recent studies began to reveal
effects of hyperphosphorylation on RPA-DNA and RPA-protein interactions (Binz et al., 2004;
Block et al., 2004; Iftode et al., 1999; Liu and Weaver, 1993; Zernik-Kobak et al., 1997; Zou et
al., 2006). A recent review on RPA phosphorylation by Binz et al. (Binz et al., 2004) has
suggested that hyperphosphorylation may make RPA less active in DNA replication and help the
transition of RPA from replication to DNA damage response including DNA repair. However,
how this occurs and the potential structural changes of RPA after hyperphosphorylation remain
unknown.
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DNA Repair Defects in Laminopathy-Based Premature Aging
Recent studies showed that DNA damage accumulation and DNA damage responses
resulting from repair defects can cause phenotypes reminiscent of premature ageing and may
have causal roles in normal aging (Lombard et al., 2005). These DNA repair defects are usually
caused by mutations in genes encoding DNA repair proteins (Karanjawala and Lieber, 2004;
Lombard et al., 2005). Two premature aging diseases caused by defective maturation of lamin A
have been recently found to involve DNA repair defects (Liu et al., 2005a; Varela et al., 2005).
Lamin A is a component of nuclear lamina that functions to structurally support the nucleus and
organize chromatin (Goldman et al., 2002). One of the diseases is Hutchinson-Gilford progeria
syndrome (HGPS), which is rare (1 in 4 million children) and uniformly fatal. HGPS is
characterized by retarded growth, partial lipodystrophy, osteoporosis, osteolytic lesions, thin
skin, micrognathia, and premature atherosclerosis (Eriksson et al., 2003). All patients die as a
consequence of myocardial infarction or cerebrovascular accident at an average age of 12 years
(range from 8 to 21 years) (Capell et al., 2005). The defective maturation of Lamin A from its
precursor, prelamin A, in HGPS is caused by a de novo point mutation (1824C → T) in the
LMNA gene (De Sandre-Giovannoli et al., 2003; Eriksson et al., 2003).. This mutation results in
a deletion of 50 amino acids near the C terminus of prelamin A including an endoprotease
(Zmpste 24) cleavage site required for the proteolytic maturation of lamin A (Eriksson et al.,
2003). The consequence of this mutation is the accumulation of a truncated prelamin A,
progerin, in the patient cells. Another premature aging disease is restrictive dermopathy (RD).
RD is neonatally lethal, characterized by retarded growth, tight and rigid skin, alopecia,
micrognathia, and other bone abnormalities (Navarro et al., 2005). The defective maturation of
lamin A in RD is caused by the deficiency of protease Zmpste 24, which results in the
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accumulation of prelamin A in cells. HGPS and RD have been suggested to be manifestations of
the same cellular problem to different degrees (Misteli and Scaffidi, 2005). Recent studies
showed that the genomic integrity has been compromised and DNA repair is defective in human
HGPS fibroblasts and Zmpste24-deficient mouse embryonic fibroblasts (MEFs) (Liu et al.,
2005a) (Varela et al., 2005). Moreover, an active p53 signalling pathway exists in Zmpste24deficient MEF (Varela et al., 2005). The question remaining to be answered is, why is DNA
repair compromised in HGPS and RD cells when the defects are in the nuclear structural protein
lamin A and no evidence of mutations were found in repair genes?

Questions to be Answered in the Studies
In NER, RPA together with XPA and XPC-hHR23B are believed to be the DNA damage
recognition factors. It is widely accepted that the XPA-RPA complex functions in verifying the
presence of DNA lesions following the initial damage recognition by the XPC-hHR23B complex
in a double-checking mechanism (Evans et al., 1997; Missura et al., 2001; Sugasawa et al., 1998;
Thoma and Vasquez, 2003). But how the DNA lesions are verified and the exact spatial
arrangement of the recognition factors at the damage site remain unknown. Controversial results
have been shown regarding the relative binding affinities of RPA with damaged or undamaged
ssDNA (Hey et al., 2001; Lao et al., 2000; Patrick and Turchi, 1999; Patrick and Turchi, 2001;
Schweizer et al., 1999). The apparent inconsistency has resulted in the notion that RPA binds
preferentially to either undamaged or damaged ssDNA strand or both strands of DNA duplex
that have been disrupted by a lesion. To clarify this inconsistency, the binding of RPA to a
battery of well-defined ssDNA substrates containing different adducts was systematically
examined using noninvasive fluorescence spectroscopy. This work has been published in
Biochemical Journal (2005, 385:519-526) (Liu et al., 2005c) and is presented here as Chapter 2.
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Although RPA hyperphosphorylation has been observed for more than a decade, the
effects of hyperphosphorylation on RPA-DNA and RPA-protein interactions are only beginning
to be elucidated. One of the most challenging issues regarding the cellular role of RPA
hyperphosphorylation is how the functions of RPA, mediated by its interactions with DNA and
proteins, are modulated by hyperphosphorylation. There are two possible mechanisms by which
the modulation can be achieved: (i) the recognition of the hyperphosphorylated domain of RPA
by hyperphospho-binding proteins; and (ii) a hyperphosphorylation-induced structural
transformation of RPA affecting RPA-DNA and RPA-protein interactions. The potential
structural change of RPA upon hyperphosphorylation was probed using mass spectrometric
protein footprinting, fluorescence spectroscopy, and limited proteolysis. The effect of
hyperphosphorylation on RPA-ssDNA binding was also examined. This work has been
published in The Journal of Biological Chemistry (2005, 280:32775-32783) (Liu et al., 2005b)
and is presented here as Chapter 3.
Mutations in genes encoding proteins involved in DNA repair may result in defective
DNA repair, leading to DNA damage accumulation and DNA damage responses that can cause
phenotypes reminiscent of premature ageing and may have causal roles in normal aging
(Karanjawala and Lieber, 2004; Lombard et al., 2005). However, HGPS and RD cells that show
no mutations in DNA repair genes exhibit DSB accumulation, impairment of DNA repair, and
activation of the p53-dependent stress signaling pathway (Liu et al., 2005a; Manju et al., 2006;
Varela et al., 2005). This suggestes that genome instability caused by HGPS and RD might
contribute to premature aging. To find out whether DNA damage responses similar to those
caused by deficient DNA repair proteins exist in HGPS and RD, the activation of DNA damage
checkpoints in the patient cells has been investigated. The results were summarized in a

26

manuscript “DNA Damage Responses in Progeroid Syndromes Arising from Defective
Maturation of Prelamin A”, which has been accepted by Journal of Cell Science (in press) (Liu et
al., 2006b). This work is present here as Chapter 4. Further studies were conducted to find out
the causes of DNA repair defects in the patient cells. Using immunofluorescence microscopy and
chromatin immunoprecipitation (ChIP) assay, we examined the localization of DNA repair
poroteins in relation to DSB sites. The results were summarized in a manuscript “Xeroderma
Pigmentosum Group A (XPA) Inhibits Repair of DNA Double-Strand Breaks in LaminopathyBased Premature Aging Cells” and submitted to Journal of Cell Science. The manuscript is
currently under the process of review. This work is presented here as Chapter 5.
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CHAPTER 2

INTERACTIONS OF HUMAN REPLICATION PROTEIN A WITH SINGLE-STRANDED
DNA ADDUCTS

Abstract
Human replication protein A (hRPA), a single-stranded DNA-binding protein, is required
for many cellular pathways including DNA repair, recombination, and replication. However, the
role of RPA in nucleotide excision repair remains elusive. In the present study, we have
systematically examined the binding of RPA to a battery of well-defined ssDNA (single-stranded
DNA) substrates using fluorescence spectroscopy. These substrates contain adducts of (6-4)
photoproducts, N-acetyl-2-aminofluorene-, 1-aminopyrene-, BPDE (benzo[a]pyrene diol
epoxide)- and fluorescein that are different in many aspects such as molecular structure and size,
DNA disruption mode (e.g. base stacking or non-stacking), as well as chemical properties. Our
results showed that RPA has a lower binding affinity for damaged ssDNA than for non-damaged
ssDNA and that the affinity of RPA for damaged ssDNA depends on the type of adduct.
Interestingly, the bulkier lesions have a greater effect. With a fluorescent base-stacking bulky
adduct, (+)-cis-anti-BPDE-dG, we demonstrated that on binding of RPA the fluorescence of
BPDE-ssDNA was significantly enhanced by up to 8 to 9 folds. This indicated that the stacking
between the BPDE adduct and its neighbouring ssDNA bases had been disrupted and there was a
lack of substantial direct contacts between the protein residues and the lesion itself. For RPA
interaction with short damaged ssDNA, we propose that on RPA binding the modified base of
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ssDNA is looped out from the surface of the protein, permitting proper contacts of RPA with the
remaining unmodified bases.

Introduction
Human RPA (replication protein A) is a heterotrimeric protein consisting of three
subunits of 70, 32, and 14 kDa [1]. RPA plays an indispensable role in replication, NER
(nucleotide excision repair) and homologous recombination of DNA [1, 2]. The main activity of
RPA is to bind to ssDNA (single-stranded DNA) during DNA metabolism, while RPA also binds
to dsDNA with a much lower affinity. The association constant Ka for RPA–ssDNA interaction
is in the range of 108–1011 M-1 depending on the sequence and length of the ssDNA, the method
of analysis and the experimental conditions [2-4]. The affinity of RPA for pyrimidine residues is
approximately 50-fold higher than that for purine residues [5]. Structural studies revealed that
RPA contains four DBDs (DNA-binding domains). Three of them (DBD-A, -B, and -C) are
located in RPA70 in tandem with DBD-A and -B in the central region and DBD-C in the Cterminal region [6]. The fourth DBD resides in the central region of RPA32, referred to as DBDD [7, 8]. The binding of RPA to ssDNA has been suggested to occur through a multi-step
pathway [2, 7]. The binding is initiated by an interaction of the DBD-AB domains with a length
of 8–10 nt of the ssDNA [7]. Then, a significant conformational change of the protein allows
ssDNA binding between 13 and 22 nt with the DBD-C domain additionally involved [8, 9].
Finally, co-operative binding of RPA with all the four DBDs occurs, which involves a region of
30 nt [7]. It is now generally accepted that RPA needs an occluded size of approximately 30 nt
for a minimum full and high-affinity binding [1, 2, 5, 10].
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RPA has been suggested to be involved in DNA damage recognition of NER owing to its
preference for the damaged DNA relative to undamaged DNA [11-20], although the specific role
of RPA in the mechanism is not clear in recent studies [21-26]. Efforts have been made to
understand the origin of the recognition and thus the functions of RPA in NER. It has been
shown that RPA binds more efficiently to the undamaged ssDNA than to cisplatin-modified
ssDNA [13, 16, 27]. In contrast, the affinity of RPA for UV-damaged ssDNA was up to 60-fold
higher compared with that for undamaged ssDNA [12, 28]. These apparently inconsistent results
have resulted in the unclear notions that RPA binds preferentially to either undamaged ssDNA or
damaged ssDNA or both strands of DNA duplex that have been disrupted by the lesion. It has
been noted that different methods and adducts were used in these investigations. More
importantly, in most of these studies, the ssDNA substrates used were much longer than 30 nt,
the occluded binding size of RPA. Use of such long ssDNA substrates appeared to be
problematic due to the multiple binding sites available in a single ssDNA molecule and thus to
the co-operative binding of RPA molecules to ssDNA. In addition, how RPA interacts with the
adduct molecule itself in ssDNA remains unknown. Therefore, to address the controversy and to
understand better the mechanism of RPA–ssDNA adduct interactions, a systematic study of RPA
binding with well-defined damaged and undamaged ssDNA under strict conditions is necessary.
In the present study, we have systematically examined the interactions of human RPA
with a series of modified and unmodified ssDNA substrates with a single protein-binding site
(protein/ssDNA stoichiometry = 1) using the rigorous method of fluorescence anisotropy. These
substrates contain adducts that are different in molecular size and structure, DNA-interacting
structure (e.g. intercalating or non-intercalating), as well as chemical properties. Our results
showed that RPA has no binding preference for damaged ssDNA over undamaged ssDNA.
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Instead, RPA has lower binding affinities for damaged ssDNA than for undamaged ssDNA, and
the extent of decrease in binding depends on the type of adduct. Also using BPDE
(benzo[a]pyrene diol epoxide) as both a DNA adduct and a fluorescent DNA base-interaction
and stacking sensor, we have analysed the nature of adduct due to binding of RPA. The results
demonstrated that the interactions of the BPDE lesion with neighbouring bases were largely
disrupted as a result of the protein binding. However, the results also suggested that there were
no obvious direct interactions between the protein residues and the lesion itself.

Materials and Methods
DNA Substrate Preparation
Oligodeoxynucleotides with or without fluorescein modification (except 30mers) were
purchased from Qiagen (Alameda, CA, U.S.A.) in HPLC-purified quality. The 5´-fluoresceinlabelled 30mer substrates with or without adduct were constructed by ligating the 5´phosphorylated 11mer (with or without an adduct; Figure 2-1, page 32) with the 5´-fluoresceinlabelled 9mer and 5´-phosphorylated 10mer, using T4 DNA ligase. The sequences of
oligodeoxynucleotides used in the constructions are as follows: 9mer (GTTACGGCT); 11mer
[CCATCXCTACC, X=G or (+)-cis-BPDE-N2-dG or C8-AAF-dG or C8-AP-dG; here, AAF
stands for N-acetyl-2-acetylaminofluorene, AP for 1-aminopyrene, C8-AAF-dG for N(deoxyguanosin-8-yl)-AAF, and C8-AP-dG for N-(deoxyguanosin-8-yl)-AP]; and 10mer
(GCAATCAGGC). The adducted 11mer was synthesized by Dr. Nicholas E. Geacintov (New
York University, New York, New York) and Dr. Ashis K. Basu (University of Connecticut,
Storrs, Connecticut). The 5´-fluorescein-labelled 9mers (100 pmol) were incubated with
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Figure 2-1. Structures of ssDNA substrates used in the present study
(A) Schematic of ssDNA containing various modifications. F in the sequences stands for
a fluorescein modification attached through a C5-linker to the 5’- or 3’-end of the
respective ssDNA. X in the sequences represents the single adducted nucleotide. (B)
Structures of specific DNA adducts.

32

equal moles of the phosphorylated 11mer (with or without an adduct) and 10mer in the presence
of a 44mer template strand containing the complementary sequence
(GATCTGGCCTGATTGCGGTAGCGATGGAGCCGTAACAGTACGTA) in 100 ml of
ligation buffer containing 50 mM Tris/HCl (pH 7.8), 10 mM MgCl2, 10 mM dithiothreitol, 1 mM
ATP and 50 mg/ml BSA. The mixture was brought to 85 °C for 5 min and then slowly cooled
down to room temperature (25 °C) and finally to 16 °C, followed by the addition of 1 unit of T4
DNA ligase. The ligation was performed at 16 °C for 12 h. The sample was then reheated at 85
°C for 5 min with 8 M urea, followed by rapidly chilling on ice and then purified on a 12% (w/v)
polyacrylamide sequencing gel under denaturing conditions. Using the 5´-32P-labelled 30mer and
44mer as controls, the band identified as 30mer which migrated much faster than the 44mer in
the gel was excised, eluted, and precipitated with ethanol. For construction of the 29mer with or
without a (6-4)PP [(6-4)-photoproduct] adduct, the same procedures were performed, except that
the 11mer was substituted with the 10mer [CGTAT TATGC, T T=(6-4)PP] and a
complementary 35mer (TGGCCTGATTGCGCATAATACGAGCCGTAACAGTA) was used
for the ligation. The single-stranded nature of the constructed substrates was further confirmed
by the ssDNA nuclease assays with S1 enzyme. All the substrates used in the fluorescence and
anisotropy measurements are depicted in Figure 2-1 (page 32).

RPA Preparation
Recombinant human RPA was expressed in Escherichia coli BL21(DE3)-RP cells and
purified as described previously [29]. The concentration of RPA protein was determined using
Bio-Rad Protein Assay kit.
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Gel Mobility-Shift Assays
Oligonucleotides poly(dT)8, poly(dT)30, poly(dT)40, and poly(dT)50 were radiolabelled
with [γ-32P]ATP and polynucleotide kinase. The substrate (5 nM) was incubated with the
indicated amounts of RPA at 25 °C for 15 min in 20 ml of the binding buffer (40 mM Hepes–
KOH, pH 7.9, 75 mM KCl, 8 mM MgCl2, 1 mM dithiothreitol, 5% (v/v) glycerol, and 100
mg/ml BSA). After incubation, 2 ml of 80% glycerol was added, and the mixture was
immediately loaded on to a 3.5% native polyacrylamide gel in TBE running buffer (89 mM
Tris/borate, pH 8.3, and 2 M EDTA) and electrophoresed at room temperature.

Gel-Filtration Analysis and Scintillation Counting
Gel-filtration assay was performed on an HR 10/30 Superdex 200 column with an
AKTApurifier system (Amersham Biosciences, Uppsala, Sweden) followed by scintillation
counting. Poly(dT)8 and poly(dT)40 were radiolabelled with [γ-32P]ATP. Binding of RPA to these
substrates was conducted the same way as in the gel mobility-shift assays, except that it was
performed in a larger volume of 100 ml. After incubation at 25 °C for 15 min, the reaction
mixture was loaded on to the column equilibrated with the same binding buffer. Fractions of 0.5
ml were collected at 0.5 ml/min, with the radioactivity of each fraction counted using a
liquidscintillation counter. The column was calibrated with the following molecular-mass
standards: RNase A, 13.7 kDa; chymotrypsinogen A, 25 kDa; ovalbumin, 43 kDa; bovine
albumin, 67 kDa; aldolase, 158 kDa; catalase, 232 kDa; ferritin, 440 kDa; and thyroglobulin, 669
kDa.
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Fluorescence Measurement of the Binding of RPA to ssDNA with a BPDE Adduct
Measurements of the fluorescence emission spectra and the fluorescence titration were
performed as described previously [30]. Fluorescence of the BPDE-ssDNA substrates was
recorded at 25 °C on a SPEX Fluorolog-3 fluorimeter (Jobin Yvon, Edison, NJ, U.S.A.) with the
excitation wavelength set at 350 nm, the slit width set at 5 nm for both excitation and emission
beams and the integration time set at 0.5 second. Not more than 5% photobleaching was
observed under these conditions. For titration, analysis was performed by measuring the
emission at 380 nm with excitation at 350 nm. After sample equilibration, three data points with
an integration time of 5 seconds and S.E.M. of 0.5% were collected for each titration point. RPA
and the DNA substrates were placed in the same binding buffer before the titration to eliminate
any change of the background on the addition of protein. All titrations were performed in a
micro-quartz cuvette (4 mm × 4 mm) for a minimum sample volume of 200 µl with a 2 mm×2
mm stirring bar. Each addition of RPA was 0.5–1 µl, delivered by a 25-µl Hamilton syringe
using a Hamilton repeating dispenser.

Fluorescence Anisotropy Measurements
Measurements of fluorescence anisotropy provide information about the rotational
behaviour of molecules. On binding of the fluorescently labelled DNA probe to proteins, the
fluorescence anisotropy of the probe increased, serving as an indicator of the complex formation
[16]. In the present investigation, ssDNA with fluorescein labelling at the 5´-end was used to
monitor the RPA–ssDNA binding. The reason for choosing 5´-modification instead of 3´modification is that, with the ssDNA fluorescein-labelled at the 5´-end, the intensities and shapes
of the fluorescence spectra observed before and after the addition of saturating RPA
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concentrations showed virtually no changes; however, with 3´-labelling the total fluorescence
intensity decreased by approximately 30% upon binding.
The anisotropy titrations were performed on a SPEX Fluorolog-3 fluorimeter with
automated polarizers at an excitation wavelength of 492 nm and monitored at an emission
wavelength of 520 nm using a 500-nm cutoff filter with the slit width set at 14 nm for both
excitation and emission beams for reliable signals. Other titrations were performed with the same
procedure as described in the above fluorescence titrations of BPDE-DNA substrates.

Data Processing
Three measurements of fluorescence titration or anisotropy titration for each sample were
performed independently. The obtained data were expressed as mean value with standard
diviation. The data were then processed to determine the equilibrium dissociation constant
(Kd,obs) or binding constant (Kobs) using a one-site binding model and the non-linear least-squares
method as described below [30].
For the equilibrium interaction of protein with DNA substrate:
P + DNA

P · DNA

K = [PD] / [P][D]

[1]

For the spectroscopic titration, we have:
∆I = k[D]tK[P] / (1 + K[P])

[2]

where ∆I represents fluorescence intensity change or anisotropy change, k is the proportional
constant, and [D]t stands for the total concentration of DNA, which is known.
From equation [1], it can be derived that:
K = [PD]/([D]t – [PD])([P]t – [PD])

[3]
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where [P]t is the total concentration of protein. Therefore, if the binding constant is known, the
equilibrium free concentrations of RPA or DNA-bound RPA in the solution at all titration points
can be determined by the following expression:
[PD] = (-b ± (b2-4ac)1/2) / 2a

[4]

where a = K, b = −K([D]t + [P]t) − 1, and c = K[D]t[P]t.
To obtain the binding constant K from the best fits of equation [2] to the data, an iteration
process was established with [2] and [4] in the following fashion. (a) An initial estimated K was
used in equation [4] to obtain the equilibrum free concentration of protein ([P] = [P]t − [PD])
corresponding to each experimental [P]t. (b) The determined free protein concentration was then
applied in equation [2] to calculate the new K and k by a non-linear least-squares fit. (c) Steps (a)
and (b) were repeated with the newly determined protein free concentrations until the iteration
process led to a convergence where the values of the equilibrium binding constant and protein
free concentrations were no longer changed within the error limit (10−5).

Results
Stoichiometry of RPA Binding to Different Sizes of ssDNA
RPA needs an occluded binding site of approximately 30 nt for a full and high-affinity
binding [1, 2]. However, two different modes of complexes of RPA may occur depending on the
experimental conditions [10]. To select ssDNA substrates with a binding stoichiometry of one
for the present study, we have performed gel mobility-shift assays of RPA with various sizes of
ssDNA. As shown in Figure 2-2 (page 38), of the substrates poly(dT)8, poly(dT)30, poly(dT)40,
and poly(dT)50, a single shifted band was observed with (dT)8 (not shown) and (dT)30 even in the
presence of excess protein, suggesting a single RPA binding. In contrast, an additional slower
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eluting band appeared with (dT)40 and (dT)50 as the concentration of RPA was increased to 25
nM, implying that multiple complexes may form with these longer oligonucleotides. This is not
in agreement with the previous report by Kim et al. [5] who noted only one shifting band for

Figure 2-2. Binding of RPA to different sizes of ssDNA
RPA was incubated with 5 nM poly(dT)8, poly(dT)30, poly(dT)40, or poly(dT)50 at different molar
ratios (0, 1, and 5) at 25 ºC for 15 minutes in 20 µL of the binding buffer. The binding products
were analyzed on a 3.5% native polyacrylamide gel. The positions of RPA-ssDNA complexes
and free oligonucleotides are indicated.

the RPA binding to (dT)50, although this may be the result of different conditions used in their
assays. It is also worth noting that the electrophoretic mobility of the RPA–ssDNA complex
increased as the length of the ssDNA increased from 8 to 40 nt, which was also noted in an
earlier study [10]. Although the conformational change of the complex might affect the mobility
[10], a more reasonable explanation could be that the ratio of the negative charges to the
molecular mass (kDa) of the complex (charge/mass) influenced the mobility as a function of the
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length of ssDNA. These ratios are consistent with the migration pattern observed with a single
bound RPA.
To define the nature and stoichiometry of these complexes, a gel-filtration assay followed
by scintillation counting was performed to determine the molecular masses of the complexes
formed between radiolabelled (dT)8 or (dT)40 and RPA at different concentrations. Figure 2-3A
(page 40) shows the elution profile of the RPA–DNA binding reaction mixtures, in which the
two major peaks represent two types of DNA–protein complexes. When 10 times more RPA (in
molar ratio) was incubated with (dT)8, a single peak appeared at 11.5 ml, which was also the
retention volume for the RPA–(dT)40 complex at a protein/DNA ratio of 1:1. The low peak
intensity for (dT)8 was due to the less efficient 32P-labelling and the much lower binding affinity
of RPA for such short substrates compared with d(T)40. Calculations based on mass standards
showed that the retention volume of 11.5 ml corresponds to a molecular mass of 130 kDa (Figure
2-3B, page 40), which is consistent with the binding of a single RPA molecule in both cases. In
contrast, incubation of the protein with (dT)40 in a 10:1 ratio resulted in an RPA–(dT)40 complex
with a retention volume of 10.0 ml, which corresponds to a molecular mass of 238 kDa. This is
consistent with a double-bound complex (RPA/DNA=2). Therefore, the (dT)40 ssDNA allows
double bindings by RPA, whereas (dT)8 permits only single binding and the complex has a
molecular mass similar to the complex from RPA–(dT)40 single binding. Most probably, the
single binding also occurred for (dT)30 ssDNA. Thus we conclude that a length of 30 nt is
sufficient for the binding of one RPA molecule under our experimental conditions.
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Figure 2-3. Gel filtration analysis of RPA-ssDNA binding
(A) Scintillation counting of RPA binding reactions with different sizes of ssDNA. The
binding reactions of RPA with poly(dT)8 and poly(dT)40 at different molar ratios were
constructed and gel-filtrated as described under Materials and Methods. (B) The apparent
molecular masses of the RPA-ssDNA complexes were determined by gel filtration based on
the relationship of the retention volumes of markers versus their molecular masses fitted with
linear regression method.
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Fluorescence Spectroscopic Characterization of RPA Binding to Defined Substrates
Little is known about how RPA protein interacts with the adduct molecule of the damaged
ssDNA. In the present study, we examined RPA binding to oligonucleotides containing a single
BPDE lesion by monitoring the fluorescence of BPDE. Because aromatic amino acids are
probably involved in the interactions of RPA with normal ssDNA through stacking with bases
[4, 7, 31], it is of interest to determine how the pyrene-like residue of the BPDE-N2-dG adduct is
affected. The fluorescence of this adduct is a very sensitive probe of its environment and we
have previously used this in the study of a protein–DNA interaction system [30]. It is now
known that the fluorescence of the pyrenyl residue of BPDE-N2-dG adducts in DNA is strongly
quenched [32] by neighbouring T and C bases [33]. In DNA, the fluorescence of BPDE-N2-dG
adducts is sensitive to the secondary structure, the aqueous solvent environment [32], and the
adduct conformation [34]. Therefore, any disruption or weakening of the BPDE-base interactions
may lead to an increase in the fluorescence of the adduct, providing evidence for structural
alterations in the immediate environment of BPDE-N2-dG lesions. In ssDNA, significant BPDE–
base stacking interactions are evident since the absorption spectrum of the prenyl residue is
significantly red-shifted with an absorption maximum at approximately 352–354 nm [35]. When
excited at 350 nm, the emission spectrum of the BPDE-adducted 11mer oligonucleotides (Figure
2-1, page 32) displays two fluorescence maxima, one at 384 nm and the other at 404 nm,
consistent with previous observations [30, 36]. After binding to RPA, the λmax at 384 nm blueshifted to 380 nm, and the fluorescence intensity was enhanced by 8–9-fold (Figure 2-4A, page
43, and Table 2-1, page 42). This implies that, on binding of RPA, the interactions between the
BPDE molecule and the neighbouring bases were lost due to a local conformational change in
the ssDNA. This leads to diminished BPDE–nucleobase stacking interactions as indicated by a
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significant blue shift in the fluorescence emission maxima and a large enhancement in the
fluorescence yield. A (+)-cis-BPDE-30mer ssDNA substrate was also subjected to the same
measurements. While similar results were observed, the fluorescence enhancement was not as
large as with the BPDE-11mer (Table 2-1). It is probable that the BPDE molecule remained
partially stacked in this case. Furthermore, these results suggested that no significant interactions
between RPA residues and the BPDE molecule occurred. Otherwise, fluorescence quenching
rather than enhancement would be observed upon RPA interaction.
In comparison, emission spectra for a non-stacking fluorescein, site-specifically adducted
to the middle of a 9mer ssDNA, F(M)-9mer (Figure 2-1, page 32), were recorded with λex =492
nm in the presence and absence of RPA (Figure 2-4B, page 43). No fluorescence variation was
observed, indicating that fluorescence quenching interactions are absent from such adducts.
Unlike the (+)-cis-BPDE-dG adduct, the fluorescein derivative is covalently attached to the
nucleic acids of ssDNA through a long carbon linker.
Table 2-1. RPA binding to damaged / undamaged ssDNA
Fluorescence enhancement
ssDNA

Kd,obs (nM)

5’F-9mer

39.1 ± 4.5

5’F-Abase(M)-9mer

43.0 + 1.5

F(M)-9mer

93.7 ± 6.2

5’F-11mer

22.9 ± 2.6

BPDE-11mer
5’F-30mer

146.0 ± 6.7
11.8 ± 1.5

5’F-AAF-30mer

9.0 ± 1.9

5’F-(6-4) PP-29mer

8-9

2.5 ± 0.4

5’F-BPDE-30mer
5’F-AP-30mer

upon RPA binding (fold)

16.5 ± 3.1
6.1 ± 0.4
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Figure 2-4. Fluorescence spectroscopic characterization of RPA binding to defined ssDNA
(A) The emission spectra of (+)-cis-BPDE-11mer in the absence and presence of RPA were
recorded with the excitation at 350 nm in 200 µL of RPA binding buffer. (B) The fluorescence
spectra of a 9mer with fluorescein modification in the middle of the sequence or at 5’-end in the
absence and presence of RPA were recorded with the excitation at 492 nm in RPA binding
buffer. (C) The fluorescence spectra of a 11mer with fluorescein labeling at 3’-end in the absence
and presence of RPA were recorded as in (B). All the fluorescence measurement was presented
in arbitrary units.

Additional structural information about the RPA–ssDNA interaction was obtained from
fluorescence spectroscopic studies with a fluorescein labelled at either the 5´- or 3´-end ssDNA
(Figures 2-4B and 2-4C, page 43). The fluorescence of the probe labelled at the 3´-end of ssDNA
was quenched by approximately 30% on RPA–ssDNA complex formation, which was consistent
with the results observed previously [16]. Interestingly, the binding of RPA to the ssDNA with
the fluorescein labelled at the 5´-end led to no change in fluorescence, regardless of the length of
the substrate. This implies that the 5´-terminus of ssDNA had no direct contact with RPA
protein, while the 3´-end did.

RPA Binding to 5´F-30mer with or without (6-4)PP, BPDE, AAF, or AP Adduct
Experiments were conducted to assess the binding affinities of RPA with a series of
damaged and undamaged ssDNAs of 9mer, 11mer, and 30mer nucleotides. Use of such short
substrates eliminated the possibility of overlapping binding sites that are usually available with
longer ssDNAs. In addition, for RPA interaction with damaged ssDNA, the protein may bind to
the flanking undamaged DNA sequence of a lesion if the size of the substrate is too long and
direct contact of RPA with the DNA lesion is thermodynamically unfavourable. Because a size
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of approximately 30 nt is the minimum length of ssDNA required for RPA to have a full
functional interaction with ssDNA, we first examined RPA binding to the 30mer ssDNAs
containing different types of adduct using fluorescence spectroscopy. All the substrates were 5´terminally labelled with fluorescein and used as substrates for fluorescence anisotropy
measurements. The fluorescence intensity of fluorescein modified either at the 5´-end or in the
middle of the sequence of ssDNA remained unaffected by RPA binding, indicating that there
was no direct interaction of the protein with the fluorescein. This established the validity of the
fluorescence anisotropy measurements. For the 3´-terminally labelled fluorescein, the
fluorescence intensity changed due to RPA binding (Figure 2-4C, page 43). Therefore, the 3´fluorescein is not suitable for use as a reporter for anisotropy measurements, although it was used
previously for the determination of RPA–ssDNA interactions [16]. In addition, although the
BPDE, AAF, and AP have intrinsic fluorescence when excited at appropriate wavelengths,
emissions of these adducts occur at the wavelength range far shorter than 492 nm, the excitation
wavelength for producing the anisotropy of fluorescein. Therefore, it is unlikely that the adduct
fluorophore would interfere with the fluorescence of fluorescein through dipole–dipole coupling.
Table 2-2 (page 46) shows the data collected from the fluorescence anisotropy titration of RPA
binding to the 30mers adducted with or without BPDE. Figure 2-5 (page 47) shows the
representative isotherms by fitting the data in a one-site binding model. As shown in Table 2-1
(page 42), RPA binding affinities for the substrates followed the order: ND>(64)PP>AAF>BPDE>AP, where ND stands for non-damaged ssDNA, suggesting that RPA binds
less efficiently to these adducts than to the non-damaged ssDNA.
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Table 2-2. Fluoresecence anisotropy titration of RPA binding to 5’F-30mer or 5’F-BPDE-30mer
5’F-BPDE-30mer

5’F-30mer
RPA(nM)

Mean

Std

Mean

Std

0

0

0

0

0

0.5

0.0054

0.0012

0.0029

0.0008

1

0.0103

0.0014

0.0062

0.0006

1.5

0.0158

0.0021

0.0092

0.0006

2

0.0211

0.0030

0.0123

0.0009

2.5

0.0262

0.0029

0.0157

0.0008

3.5

0.0368

0.0032

0.0224

0.0024

4.5

0.0457

0.0029

0.0275

0.0015

5.5

0.0537

0.0029

0.0326

0.0018

6.5

0.0611

0.0027

0.0372

0.0020

7.5

0.0654

0.0029

0.0418

0.0023

9.5

0.0691

0.0021

0.0481

0.0033

11.5

0.0731

0.0019

0.0539

0.0047

13.5

0.0763

0.0018

0.0583

0.0030

15.5

0.0785

0.0027

0.0627

0.0029

17.5

0.0806

0.0016

0.0668

0.0030

21.5

0.0827

0.0016

0.0713

0.0020

25.5

0.0856

0.0017

0.0743

0.0017

29.5

0.0864

0.0019

0.0774

0.0032

33.5

0.0873

0.0019

0.0799

0.0028

37.5

0.0889

0.0023

0.0816

0.0026

Mean represents the mean value of three measurements for each titration point;
Std represents the standard deviation.
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Figure 2-5. Fluorescence anisotropy titration of RPA binding to 5’F-30mer or 5’F-BPDE-30mer
Five nanomolar 5’F-30mer or 5’F-BPDE-30mer was titrated with RPA. The binding isotherms
were best fitted to obtain the equilibrium dissociation constants (Kd,obs). Each datum point was
the mean value of three independent measurements. Error bars represent standard deviations.
To verify that the anisotropy titration and fluorescence titration gave the same results for
RPA binding to BPDE-adducted ssDNA, titration was also conducted by measuring the BPDE
fluorescence change of 5´F-BPDE-30mer. A non-linear least-squares fit of the data provided a
dissociation constant of 14.1 nM. This is evidently in good agreement with the value of 11.8 nM
determined from the anisotropy measurement, indicating the reliability of these two approaches
used in our binding experiments.
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RPA Binding to Damaged and Undamaged 9mer and 11mer ssDNAs
We also examined the RPA binding to the damaged F(M)-9mer and undamaged 5´F-9mer
ssDNAs by titrational fluorescence anisotropy measurements. For the substrate F(M)-9mer, the
fluorescein also was considered as a lesion in the ssDNA. Figure 2-6A (page 50) showed the
RPA-binding isotherms of titration data with substrates 5´F-9mer and F(M)-9mer (Table 2-3,
page 49). The anisotropy data were normalized by subtracting the initial value of the respective
free DNA and best fitted with the procedures described previously [30]. The results indicated
that the affinity of RPA for the 5´F-9mer was significantly higher than that for the F(M)-9mer
(Table 2-1, page 42), as demonstrated by the values of dissociation constants 39.1±4.5 and
93.7±6.2 nM for 5´F-9mer and F(M)-9mer respectively. Because the centrally located
fluorescein was not attached to a base, the same anisotropic measurement was conducted for
RPA binding to a 9mer (5´-end labelled with fluorescein) containing an abasic site in the middle
of the same sequence (CATC[abase]CTAC). The binding affinity of RPA for this abasic
substrate is very close to that for the undamaged 5´F-9mer (Table 2-1, page 42), indicating that
the lack of base in the middle nucleotide had no effect on RPA binding. Thus, the decrease in the
affinity for the F(M)-9mer was attributed to the presence of the fluorescein in the middle of the
9mer, although there was no direct interaction between the protein and the aromatic moiety of
the fluorophore.
To determine how a base-stacking aromatic lesion adducted directly to a base influences
RPA binding, BPDE, a different type of adduct with a larger aromatic ring system (Figure 2-1,
page 32) was introduced into the 11mer. As described earlier, binding of RPA to BPDE-adducted
ssDNA led to a large fluorescence enhancement. This fluorescence change can be used as a
signal to monitor RPA–ssDNA interactions and to generate binding isotherms. As shown in
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Table 2-4 (page 51) and Figure 2-6 B and C (page 50), titrations of RPA binding to the BPDEssDNA 11mer and the normal 11mer with the same sequence were performed and the binding
affinities were determined for comparison. The dissociation constant for the damaged 11mer was
146.0±6.7 nM, while that for the undamaged 11mer ssDNA was 22.9±2.6 nM, indicating a much
tighter binding with the undamaged DNA.

Table 2-3. Fluoresecence anisotropy titration of RPA binding to 5’F-9mer or F(M)-9mer
5’F-9mer
RPA(nM)

Mean

F(M)-9mer
Std

Mean

Std

0

0

0

0

0

4

0.0114

0.0010

0.0056

0.0007

8

0.0217

0.0015

0.0110

0.0008

12

0.0303

0.0016

0.0157

0.0008

16

0.0378

0.0025

0.0195

0.0010

20

0.0445

0.0022

0.0235

0.0013

28

0.0577

0.0020

0.0323

0.0017

36

0.0680

0.0017

0.0396

0.0024

44

0.0757

0.0008

0.0464

0.0030

52

0.0826

0.0007

0.0508

0.0026

68

0.0914

0.0010

0.0586

0.0024

84

0.0979

0.0003

0.0648

0.0027

116

0.1050

0.0005

0.0774

0.0039

148

0.1112

0.0018

0.0869

0.0037

212

0.1173

0.0021

0.0998

0.0034

276

0.1209

0.0019

0.1097

0.0025

Mean represents the mean value of three measurements for each titration point;
Std represents the standard deviation.
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Figure 2-6. Typical fluorescence binding isotherms for short ssDNA titrated with RPA
(A) Fluorescence anisotropy measurements of RPA binding to 5’F-9mer and F(M)-9mer. (B)
Fluorescence titration of BPDE-11mer with RPA. Error bars are too small to see. (C)
Fluorescence anisotropy titration of 5’F-11mer with RPA. Data were collected from three
independent measurements. Error bars represent standard deviations.
Table 2-4. Fluoresecence titration of RPA binding to BPDE-11mer or 5’F-11mer
5’F-11mer

BPDE-11mer
RPA(nM)

Mean

Std

RPA (nM)

Mean

Std

0

0

0

0

0

0

2

0.1381

0.0140

1

0.0032

0.0008

4

0.2841

0.0235

2

0.0063

0.0016

6

0.4232

0.0408

3

0.0092

0.0019

10

0.6777

0.0426

5

0.0156

0.0019

14

0.9041

0.0522

7

0.0202

0.0019

18

1.1148

0.0546

9

0.0251

0.0015

26

1.6337

0.0368

13

0.0352

0.0015

34

2.1078

0.0638

17

0.0449

0.0018

42

2.5423

0.0608

21

0.0526

0.0011

58

3.2353

0.0540

29

0.0654

0.0025

74

3.8279

0.0613

37

0.0737

0.0043

90

4.3257

0.0682

45

0.0799

0.0045

122

5.3244

0.0759

61

0.089

0.0043

154

6.0574

0.0687

77

0.0946

0.0040

218

7.0585

0.0569

109

0.0994

0.0032

282

7.8296

0.0554

141

0.1032

0.0038

Mean represents the mean value of three measurements for each titration point;
Std represents the standard deviation.
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Discussion
In the present study, we have systematically analysed the interactions of RPA with a
group of damaged and undamaged ssDNA substrates by fluorescence spectroscopy under strict
and comparable experimental conditions. Unlike most previous studies, the substrates used in the
present study were no longer than 30 nt in length, which kept the binding stoichiometry at one
RPA per ssDNA to avoid potential binding complications.
Our experiments designed to probe the nature of the adduct of ssDNA on RPA binding
indicated that the protein-bound ssDNA involved a significant local structural alteration around
the lesion. This structural change probably caused the disruption of BPDE-ssDNA base stacking
and the exposure of the BPDE molecule on RPA binding, which was particularly evident for the
short substrate of BPDE-11mer. The results also suggested that the exposed BPDE lesion may be
in no or little direct contact with amino acids of RPA. For RPA binding to the BPDE-11mer, it is
probable that the modified base resides in the DBDs-AB [2] and is probably flipped out of the
protein–ssDNA interaction interface, permitting better contacts of RPA with the unmodified
bases. For BPDE-30mer, two additional DBDs, DBD-C, and DBD-D of RPA are involved in the
binding. Because binding of a protein to its substrate is a dynamic equilibrium process and RPA
has a higher affinity (at least 50-fold) for ssDNA of 30 nt or longer than that for ssDNA of 8–10
nt [3], at equilibrium almost all RPA molecules bind to ssDNA starting from the 5´-end of the
substrates. Thus, the modified base that is centrally located in the substrate sequence may reside
in the entrance region of DBD-C in the DBDs-ABCD tandem [2], which may result in different
and smaller structural changes at adduct. Because both the RPA–ssDNA binding modes of 8–10
nt and 30 nt are probably biologically important in cells (although the 8–10 nt binding mode is
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not a full-length binding) [2], our results provide valuable information on RPA–ssDNA adduct
interactions in the two cases.
The present study on RPA binding to various ssDNA substrates showed that RPA binds
to undamaged ssDNA more favourably than adducted ssDNA, indicating that the presence of
lesions in the ssDNA interrupts RPA binding. Two factors might be attributed to this
observation: space restriction and the potential repulsion between the exposed aromatic lesion
and non-hydrophobic or non-aromatic amino acids. Comparison between RPA binding to the
AAF and AP (both being C8-guanine adducts) adducted ssDNAs indicated that AP has an
apparent lower affinity than AAF (Table 2-1, page 42). This may be an indication that the larger
the aromatic rings system of the adduct, the stronger the inhibition on RPA binding (Figure 2-1,
page 32). This was also true when a comparison was made between the BPDE and fluorescein
ssDNA. The affinity for BPDE-11mer was lower than that for F(M)-9mer, although it is
generally believed that for undamaged ssDNA, longer ssDNA binds to RPA more tightly. It is
conceivable that, unlike the fluorescein, which contains a long arm stretching the aromatic rings
far away from the DNA, the large BPDE ring system is directly attached to the base.
One of the objectives of the present work was to understand better the biochemical basis
for RPA binding to ssDNA and dsDNA and to determine the roles, if any, of RPA in damage
recognition in the NER. Although RPA binds to both ssDNA and dsDNA, the binding affinity
for duplex DNA is much lower than that for ssDNA. This can be attributed to three factors. First,
the binding to ssDNA is facilitated by stacking and other interactions between DNA bases and
the residues of RPA [4, 7, 31], while formation of dsDNA eliminates most of the intermolecular
interactions due to the base-pairing and stacking. Second, the dsDNA is more rigid and thus
more resistant to being bent than the ssDNA. At least local DNA bending could be a result of
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efficient RPA binding. Third, dsDNA has a larger helix diameter relative to ssDNA, which may
make the binding to dsDNA spatially less favourable. Our results for the unfavourable binding of
RPA to damaged ssDNA compared with undamaged ssDNA suggested no direct adduct
recognition power from RPA. Several other groups have suggested that the function of RPA in
DNA damage recognition in NER is to recognize the local single-stranded character induced by
lesions in the duplex [13, 16, 19, 27, 37]. However, efficient binding of RPA to the ssDNA
requires a minimum length of approximately 8 nt [10, 31] and, in most of the cases, the local
DNA denaturation induced by bulky DNA lesions is much smaller than 8 nt. Based on the results
of the present study, we, therefore, propose that base stacking disruption and DNA strand
flexibility induced by the lesions may play a role in the binding of RPA to damaged DNA. The
base stacking disruption and strand flexibility would allow the exposure of the DNA bases to
specific amino acid residues of the RPA. The strand flexibility for bending could in turn
structurally facilitate intermolecular interactions. Our hypothesis was also supported by the fact
that even without any lesions RPA discriminates the ssDNA of different sequences and this
discrimination is probably based on the strength of base stacking in the sequences. Previous
studies [3, 5] reported that affinity of RPA for pyrimidine sequences was approximately 50-fold
higher than that for purine sequences. It is conceivable that this preference for pyrimidine
residues is the result of a weaker base stacking between the relatively smaller aromatic rings of
the pyrimidines compared with those of the purine residues.
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CHAPTER 3

MODULATION OF REPLICATION PROTEIN A FUNCTION BY ITS
HYPERPHOSPHORYLATION-INDUCED CONFORMATION CHANGE INVOLVING DNA
BINDING DOMAIN B

Abstract
Human replication protein A (RPA), composed of RPA70, RPA32, and RPA14 subunits,
undergoes hyperphosphorylation in cells in response to DNA damage. Hyperphosphorylation
that occurs predominately in the N-terminal region of RPA32 is believed to play a role in
modulating the cellular activities of RPA essential for almost all DNA metabolic pathways. In
order to understand how the hyperphosphorylation modulates the functions of RPA, we
compared the structural characteristics of full length native and hyperphosphorylated RPAs using
mass spectrometric protein foot-printing, fluorescence spectroscopy, and limited proteolysis. Our
mass spectrometric data showed that of 24 lysines and 18 arginines readily susceptible to small
chemical reagent modification in native RPA, the three residues K343, R335, and R382 located
in DNA binding domain B (DBD-B) of RPA70 were significantly shielded in the
hyperphosphorylated protein. Tryptophan fluorescence studies indicated significant quenching of
W361, located in the DBD-B domain, induced by hyperphosphorylation of RPA. Consistently,
DBD-B became more resistant to the limited proteolysis by chymotrypsin after RPA
hyperphosphorylation. Taken together, our results suggest that upon hyperphosphorylation of
RPA32 N-terminus (RPA32N), RPA undergoes a subtle conformational change with specific
involvement of the ssDNA binding cleft of DBD-B. Comparison of interactions of native and
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hyperphosphorylated RPAs with short single stranded oligonucleotides or partial DNA duplexes
with a short 5’ or 3’ ssDNA tails showed reduced affinity for the latter protein. We propose that
the hyperphosphorylation may play a role in modulating the cellular pathways by altering the
DBD-B-mediated RPA-DNA and RPA-protein interactions, hypothetically via the interaction of
hyperphosphorylated RPA32N with DBD-B.

Introduction
Replication protein A (RPA) is a eukaryotic single-stranded DNA (ssDNA) binding
protein essential for DNA replication, repair, recombination (1-3), and cellular DNA-damage
checkpoints (4,5). RPA is composed of three subunits, RPA70, RPA32, and RPA14, named after
their molecular weights of 70, 32, and 14 kDa, respectively. Although the structure of full length
RPA trimer remains unsolved, X-ray crystallography, NMR, and biochemical studies reveal that
RPA70 contains four domains, the N-terminal domain of RPA70, DNA-binding domain (DBD)
A, B, and C (6-8). The tandem DBD-A and DBD-B harbor the major ssDNA binding activity of
RPA heterotrimer (9). DBD-C has a conserved zinc finger (10) and exhibits low affinity for
ssDNA but interacts with the other two subunits to form a RPA trimerization core (11). RPA32
consists of three domains, including an unstructured N-terminal phosphorylation domain
(RPA32N), a central DNA-binding domain (DBD-D), and a C-terminal domain (RPA32C)
largely involved in protein-protein interactions (12-14). RPA14 is referred to as DBD-E. All the
DBDs in RPA have similar structures, built around a central OB-fold: oligosaccharide/oligonucleotide binding fold (6,7,11,12,15). However, the N-terminal domain of
RPA70 (also referred to as DBD-F or RPA70N) has been only implicated in protein-protein
interactions in DNA metabolism (1-3, 6). In contrast, DBD-E (RPA14) shows no binding affinity
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for ssDNA but is structurally important for the formation of RPA trimerization core (11, 12).
Slight differences in structure and residue compositions of the binding clefts of the DBDs may
explain their differences in ssDNA binding (16,17).
It has been reported that the N-terminal domain of RPA32 (RPA32N) becomes
phosphorylated in a cell cycle-dependent manner (18-20) and hyperphosphorylated in response
to DNA damage (21-24). The cell cycle-dependent phosphorylation is carried out by cyclindependent kinases (Cdks) and occurs at two consensus sites, Ser-23 and Ser-29 of RPA32
(19,22,25). More sites in RPA32N are phosphorylated in cells in response to DNA damage
(22,23,26) or apoptosis (27). Phospho-peptide mapping has shown that at least five sites of
RPA32N including Thr-21, Ser-23, Ser-29, Ser-33, and either Ser-11, -12, or -13, and probably
two additional sites, Ser-4 and Ser-8, can be phosphorylated in UV-irradiated HeLa cells
(22,25,28). The DNA damage-induced hyperphosphorylation of RPA32 is believed to be carried
out by the members of phosphatidyl inositol 3-kinase-like serine/threonine protein kinase (PIKK)
family that includes DNA-dependent protein kinase (DNA-PK), ataxia-telangiectasia mutated
kinase (ATM), and ATM- and Rad3-related kinase (ATR) (2,4,23,24,29-31). DNA-PK
phosphorylates RPA32 in vitro at many of the same sites that are phosphorylated in vivo in HeLa
cells after UV-irradiation (22,24,25).
One of the most striking aspects of RPA is that the protein is involved in almost all DNA
metabolic pathways in cells. It is believed that such broad cellular activities of RPA are mediated
by its interactions with ssDNA and numerous proteins engaged in cellular processes (9,14). RPA
phosphorylation may play a role in regulation of these interactions and thus the cellular functions
of RPA (24). It has been shown that RPA hyperphosphorylation down-regulates DNA replication
(24,32). In particular, hyperphosphorylation of RPA32 may modulate RPA interactions with
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DNA and proteins involved in the DNA repair and signaling pathways in response to DNA
damage (2,24). For instance, hyperphosphorylated RPA (hyp-RPA) has shown decreased
interactions with simian virus 40 (SV40) T antigen, DNA polymerase α, DNA-PK, ATM, and
p53, while the hyperphosphorylation has no effects on RPA interactions with XPA, Rad51, and
Rad52 (20,24,33-37). In addition, hyp-RPA binds double-stranded DNA (dsDNA) with a
reduced affinity (20,38), whereas the effects of hyperphosphorylation on RPA interaction with
ssDNA remain controversial (20,38,39). Despite the significant role of hyperphosphorylation of
RPA in modulating its cellular functions, the biochemical basis of the effects is still poorly
understood. A possible scenario is that RPA may change its structure or conformation upon
hyperphosphorylation and thus alter the protein activities and functions. A synthetic peptide
fragment with eight Ser/Thr substituted to Asp to mimic the hyperphosphorylated RPA32N was
shown to interact with DBD-F (RPA70N) fragment (RPA701-168) (38). However, the structural
characteristics of the hyperphosphorylated RPA trimer of full length remain to be elucidated.
In the present study, we determined the hyperphosphorylation-induced structural
alterations of human RPA protein using mass spectrometric protein foot-printing, limited
proteolysis, and tryptophan fluorescence spectroscopy. Out of 42 basic residues readily
susceptible to modification with small chemical reagents in the native protein, the three amino
acids: K343, R335, and R382 in DBD-B of RPA70 were shielded in the context of the
hyperphosphorylated RPA. Our results indicate that these residues were exclusively involved in
a limited structural alteration of the protein upon hyperphosphorylation of the RPA32 Nterminus. In particular, this local structural change showed effects on the RPA interactions with
8mer ssDNA or partial DNA duplexes containing ssDNA tails. Considering the essential role of
RPA in most of cellular DNA metabolic processes including those mediated with short ssDNA-
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associated partial DNA duplexes, our results provide the biochemical basis for the roles of
hyperphosphorylation in regulation of RPA functions.

Materials and Methods
Protein Production and Purification
Recombinant human RPA was expressed in E. coli BL21(DE3)-RP cells harboring the
plasmid pTYB-RPA and purified as previously described (40). Two RPA mutants, W107/528
and W212/361, which had all tryptophans of RPA being replaced by phenylalanine except for
residues 107 and 528 or residues 212 and 361, were expressed from BL21(DE3)-RP cells
containing the plasmids constructed by site-directed mutagenesis. The mutant proteins were
purified by the same procedures as for native RPA.

In Vitro Phosphorylation by DNA-PK
For hyperphosphorylation, the purified RPA or mutants were incubated with DNA-PK
isolated from HeLa nuclear extracts as a complex consisting of a 400kDa catalytic subunit and
the DNA-binding component of 85kDa and 70kDa Ku subunits (Promega) at 30°C for 30
minutes in the phosphorylation buffer (40 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM DTT, 200
µM ATP, and 10 µg/mL calf thymus DNA). A mock treatment of proteins was carried out in
parallel under the exact same conditions except that no ATP was added in the phosphorylation
buffer. The reaction mixtures were then loaded onto an HR10/30 Superdex 200 column equipped
with an AKTApurifier system (Amersham Pharmacia Biotech, Sweden). To purify the
hyperphosphorylated RPA, the column was pre-equilibrated with the FPLC running buffer
containing high concentration of salt (40 mM HEPES, pH 7.5, 2 M NaCl, 10 mM MgCl2, 10 µM
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ZnCl2, and 1 mM DTT) and run with the same buffer at 4 ºC. The fractions containing
hyperphosphorylated proteins or mock-treated proteins were pooled and dialyzed against RPA
storage buffer (40 mM HEPES, pH 7.5, 50 mM NaCl, 10 mM MgCl2, 10 µM ZnCl2, 1 mM
DTT, and 50% glycerol). Protein concentration was determined using Bio-Rad Protein Assay
Kit.

Chemical Modification and in Gel Proteolysis
Biotinylation of lysine residues of RPA was carried out as described previously (41).
Briefly, 2 µM hyp-RPA or RPA was incubated with N-hydroxysuccinimidobiotin (NHS-biotin,
Pierce) in 50 mM HEPES (pH 7.5), 50 mM NaCl at 25 ºC for 30 minutes. The reactions were
then quenched by addition of 10 mM lysine. The three subunits of RPA were separated by SDSPAGE and visualized by Coomassie blue stain. The corresponding bands were excised and the
gel slices were destained, dehydrated, and digested with 1 µg of trypsin (Roche) in 50 mM
NH4HCO3 at 25 ºC overnight. Proteolytic peptides were recovered and subjected to MS and
MS/MS analysis.
Modification of arginine residues was performed by incubating 2 µM hyp-RPA or RPA
with p-hydroxyphenylglyoxal (HPG, Pierce) in 50 mM HEPES / 50 mM boric acid (pH 8.0) at
37 ºC in dark for 60 minutes. The modification was quenched by addition of 100 mM arginine.
Then samples were subjected to SDS-PAGE and protein bands were excised and processed as
described above.
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MS and MS/MS Analysis
MS spectra were obtained using matrix-assisted laser desorption time of flight (MALDITOF) and quadrupole-time of flight (Q-TOF) techniques. MALDI-TOF was done by Dr.
Mamuka Kvaratskhelia (The Ohio State University, Columbus, Ohio). Q-TOF was done by Dr.
Sonja Hess (National Institutes of Health, Bethesda, Maryland). MALDI-TOF experiments were
performed using a Kratos Axima-CRF instrument (Kratos Analytical Instruments) with α-cyano4-hydroxy-cinnamic acid matrix. MS and MS/MS analyses were performed on a Micromass
(Manchester, U.K.) Q-TOF-II instrument equipped with an electrospray source and Micromass
cap-LC. Peptides were separated with a Waters Symmetry300 5 µm precolumn (Waters,
Milford, MA) and a Micro-Tech Scientific (Vista, CA) ZC-10-C18SBWX-150 column using two
sequential gradients of 5-40% acetonitrile for 35 minutes and 40-90% acetonitrile for 20 min.
MS/MS sequence data and the MASCOT automated peptide search engine
(www.matrixscience.com) were used to identify RPA peptide peaks from the NCBInr primary
sequence database, and matched peaks were then located in the primary MS spectra. Protection
events were qualitatively assigned as the appearance of a peak corresponding to a modified
peptide in the modified protein spectrum and the absence of the modification peak in the
modified hyperphosphorylated protein spectrum. A protection was considered to be significant
only when the intensity of a modifiable peak was reduced by at least 85% in the hyp-RPA
spectrum. In order to accurately identify protection events, at least two unmodified proteolytic
peptide peaks present in all four spectra (unmodified protein, modified protein, unmodified hypprotein, and modified hyp-protein) were used as controls. These control peaks served to
standardize the peak intensities in each spectrum for accurate qualitative assignment of
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protection. Data were reproducibly compiled and analyzed from six independent experimental
groups.

Fluorescence Spectroscopy Determination
The tryptophan fluorescence spectra of RPA, its mutants, and their hyperphosphorylated
forms were recorded on a SPEX Fluorolog-3 fluorometer (Jobin Yvon Inc.) with the excitation
wavelength at 295 nm and the slit widths set at 3 nm for excitation and 5 nm for emission beams.
After equilibration of 100 nM protein in RPA buffer (40 mM HEPES-KOH, pH 7.9, 75 mM
KCl, 8 mM MgCl2, 1 mM DTT, and 5% glycerol) at 25 ºC for 10 min, the fluorescence spectra
were obtained by recording emission from 310 nm to 500 nm. For the constant wavelength
analysis, the emission at 355 nm was measured with excitation at 295 nm.
The rotational behavior of fluorescently labeled molecules can be monitored by
fluorescence anisotropy. Increase of anisotropy may indicate complex formation (42).
Fluorescence anisotropy measurements were performed to compare the binding of RPA and hypRPA to an oligo(dT)8. The (dT)8 with a fluorescein labeled at 5’ end (5’F-dT8) was purchased
from Qiagen in HPLC-purified quality. The anisotropy titrations were performed as described in
chapter 2 (43) and the data were processed using a one-site binding model and the non-linear
least-squares method for the determination of the binding constants (44).

Partial Proteolysis and Identification of Proteolytic Fragments
Four microgram of recombinant human RPA or hyp-RPA was incubated with
chymotrypsin (1:80) at room temperature for the indicated periods in a reaction buffer (10 µL)
containing 40 mM HEPES, pH 7.8, 1 mM EDTA, 70 mM MgCl2, and 10 mM DTT. At each
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time point (5, 20, or 60 minutes), 2.5 µL of the reaction mixture was removed and terminated by
addition of Laemmli sample buffer and boiling for 10 minutes. The proteolytic products were
resolved by 14% SDS-PAGE and stained with SYPRO Ruby protein gel stain (Bio-Rad). After
destained with a solution containing 10% methanol and 7% acetic acid, the gel was imaged by a
PhosphorImager (FLA-5000, FUJIFILM) using 473 nm laser line. For automated N-terminal
sequencing, the proteolytic fragments separated on the 14% SDS-PAGE were transferred to a
polyvinylidene difluoride (PVDF) membrane, followed by staining with Coomassie Brilliant
Blue G-250. The protein bands of interest were excised and sent to the protein chemistry
laboratory at the University of Texas Medical Branch for sequencing.

Gel Mobility Shift Assays
ssDNA was radio-labeled with [γ-32P]ATP and T4 polynucleotide kinase. The labeled
substrate (1 nM) was then incubated with indicated amounts of hyp-RPA or RPA at room
temperature for 15 min in 20 µL of the binding buffer (40 mM HEPES-KOH, pH 7.9, 75 mM
KCl, 8 mM MgCl2, 1 mM DTT, 5% glycerol, and 100 µg/mL BSA). After incubation, 2 µL of
80% (v/v) glycerol was added, and the mixture was immediately loaded onto a 4% native
polyacrylamide gel in 1 x TBE running buffer (89 mM Tris-borate and 2 mM EDTA, pH8.3) and
electrophoresed at room temperature. The gel was then dried. The free and bound DNA was
visualized using a PhosphorImager (FLA-5000, FUJIFILM).
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Pull-Down Assays
The binding of RPA to partial DNA duplexes containing 5’-protruding 11 nucleotides
(DNA-11) or 3’-protruding 10 nucleotides (DNA-10) were investigated by a streptavidin-agarose
pull-down assay. The sequences of the oligonucleotides used to construct the partial DNA
duplexes are as follows: 55mer, BiotinGGACCTGAACACGTACGGAATTCGATATCCTCGAGCCAGATCTGCGCC AGCTGGC;
44mer, GCCAGCTGGCGCAGATCTGGCTCGAGGATATCGAATTCCG TACG; 45mer,
GCAGATCTGGCTCGAGGATATCGAATTCCGTACGTGTTCAGGT CC. The 44mer and
45mer were 5’-32P-labeled and annealed to their complementary biotinylated 55mer at a molar
ratio of 1:1, respectively. The annealing mixture was then loaded onto an 8% native
polyacrylamide gel in 1 x TBE running buffer and electrophoresed at 80 volts for 3 hours at
room temperature. Using the 5’-32P-labeled 44mer, 45mer, and 55mer as controls, the bands
identified as the partial DNA duplexes, which migrated slower than the single-stranded
oligonucleotides in the gel, were excised, eluted, and precipitated with ethanol. After the
purification, 5 pmol of the partial DNA duplex were incubated with the indicated amounts of
mixed hyp-RPA and RPA in 500 µL of the binding buffer at room temperature for 15 minutes.
Then 20 µL of streptavidin-conjugated agarose beads (Invitrogen) pre-washed with the binding
buffer was added. The mixture was placed on a rotating shaker with gentle mixing at room
temperature for 30 minutes. The beads were collected by centrifugation and washed 3 times with
the binding buffer. The proteins in the complex were assessed by Western blotting using an
antibody specific for RPA32 as described below.
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Western Blotting
Protein samples were separated by 10% SDS-PAGE and transferred to a PVDF
membrane in Tris-glycine buffer (0.375 M Tris, 0.192 M glycine, 20% methanol). The
membrane was blocked with 5% nonfat milk at room temperature for 1 hour and then treated
with a monoclonal anti-RPA32 antibody (Kamiya Biomedical) at 0.5 µg/mL in PBS
supplemented with 5% nonfat milk at 4 ºC overnight with shaking. The RPA32 protein bands
were visualized using anti-mouse IgG conjugated with horseradish peroxidase as the secondary
antibody (Santa Cruz) by following the protocol of the ECL Western Blotting System
(Amersham Biosciences).

Results
In Vitro Hyperphosphorylation of RPA by DNA-PK
It has been well established that DNA-PK is involved in the DNA damage-induced RPA
hyperphosphorylation in cells (23,29-31,39,45-47). DNA-PK is composed of the Ku70/80
heterodimer and the catalytic subunit DNA-PKcs (48). The sites of RPA phosphorylated by
DNA-PK in vitro are similar to those phosphorylated in vivo after UV-irradiation of human cells
(22,25). Although RPA may also be hyperphosphorylated by other PIKK family members such
as ATR and ATM in response to DNA damage in vivo, hyperphosphorylation of RPA by DNAPK represents a typical one for study of the DNA damage-induced RPA hyperphosphorylation.
To investigate the changes of RPA structure and activity upon hyperphosphorylation, we
prepared the hyperphosphorylated RPA by incubating purified recombinant RPA with DNA-PK
in the presence of calf thymus DNA (Promega). After hyperphosphorylation reaction, the RPA
(116 kDa) was separated from DNA-PK (three subunits: 400, 80, and 85 kDa respectively) and
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DNA by gel filtration with the running buffer containing 2 M NaCl, followed by dialysis against
RPA storage buffer. A high salt concentration was used to dissociate RPA from the kinase and
DNA, while the RPA remained in the form of trimer (Figure 3-1A, page 71). The SDS-PAGE
and Western Blotting analyses of the RPA hyperphosphorylation showed that more than 85% of
RPA32 was hyperphosphorylated by DNA-PK as indicated by the band shifted from the native
RPA32 (Figure 3-1A, lane 3 and Figure 3-1B, lane 1, page 71). And this phosphorylation was
fully reversed after the treatment of the hyp-RPA with calf intestinal phosphatase (CIP) as the
retardation was diminished (Figure 3-1A, lane 4, page 71). No phosphorylation by DNA-PK was
observed in RPA70 and RPA14 subunits, as confirmed by the labeling with [γ-32P]ATP (data not
shown), which is also in agreement with that of a previous report (49). It has been generally
known that in vivo phosphorylation results in five isoforms of RPA that represent different levels
of phosphorylation as indicated by the mobility shifts of RPA32 on SDS-PAGE (20-22,50)
(Figure 3-1B, lane 3, page 71). Of them, forms 2-3 occur in a cell cycle dependent manner, while
forms 4-5 are the hyperphosphorylated RPA32 and appear upon cellular DNA damage.
Comparison of RPAs phosphorylated in vitro and in vivo by Western blotting revealed that most
of the DNA-PK-hyperphosphorylated RPA had the same mobility shifts as did forms 4 and 5 of
RPA from UV-irradiated HeLa cells.
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Figure 3-1. in vitro phosphorylation of RPA by DNA-PK
(A) The phosphorylation reaction was conducted as described in Experimental Procedures.
Proteins including untreated RPA (lane 1), mock-treated RPA (lane 2), hyp-RPA (lane 3), and
CIP-treated hyp-RPA (lane 4) were visualized by 14% SDS-PAGE and Coomassie blue staining.
(B) Immunoblot of RPA32 from RPA hyperphosphorylated by DNA-PK (lane 1), RPA (lane 2),
and RPA in UV-irradiated HeLa cells (lane 3). To prepare the RPA in UV-irradiated HeLa cells,
whole cell lysates were prepared from HeLa cells at 8 h following irradiation with 20 J/m2 UV.
Proteins were separated on a 10% SDS-PAGE followed by Western blotting using an antibody
specific for RPA32.
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Surface Topology Analysis of Native and Hyperphosphorylated RPAs with Group Specific
Reagents and Mass Spectrometry
Chemical modifications coupled with mass spectrometry have been used to probe the
surface topology of proteins (51-53). Recently, a strategy of protein footprinting has been
developed by Kvaratskhelia et al. for accurate mapping of protein-nucleic acid interactions using
mass spectrometry (54). Here we extend this method to probe conformational changes of RPA
after hyperphosphorylation by monitoring the changes of surface accessibility of lysine and
arginine residues susceptible to NHS-biotin and hydroxyphenylglyoxal (HPG) modifications,
respectively. Comparison of surface topologies of native and hyperphosphorylated RPAs would
enable us to identify conformational changes in the full length protein induced by
hyperphosphorylation.
Of note, maintenance of the structural integrity of proteins under the modification
conditions is crucial for the success of these experiments. Therefore, we optimized
concentrations of NHS-biotin and HPG. Our recent work indicated that upon treatment of RPAssDNA complex with 400 µM NHS-biotin the integrity of nucleoprotein complex was fully
preserved (41). Therefore, in the present study we employed the same reaction conditions. A
similar approach was used to optimize the HPG modification. We found that integrity of RPAssDNA complex was fully preserved with treatment of 1.25 mM HPG and employed this
concentration in the present study.
NHS-biotin reacts specifically with primary amines on the surface of proteins, resulting
in covalent addition of a biotin molecule (226 Daltons) to lysine and release of an Nhydroxysuccinimide (54). The modified residues could be readily identified with subsequent MS
and MS/MS analysis of the proteolytic fragments. We have recently reported NHS-biotin
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Table 3-1. Identification of modified lysines or arginines in RPA and hyp-RPA
RPA Subunits

Biotin-Modified Lysinesa

HPG-Modified Argininesa

RPA70

88, 163, 167, 183, 206, 220, 244,

91, 92, 202, 210, 216, 335, 382,

263, 259, 324, 331, 343, 379, 489,

472, 573, 575, 586, 600, 604, 605,

502, 577, 588, 595

611

RPA32

38, 93, 138, 139

40, 133

RPA14

33, 49

30

a. The residues that were protected from modification in hyper-RPA are indicated in bold
and underlined.

modification pattern of the full length RPA and RPA-ssDNA complex (41). In the present study,
we compared the biotinylation sites of the native and hyp-RPA proteins by MALDI-TOF.
Twenty-four biotinylated tryptic peptides were identified for native RPA including 18 fragments
from RPA70, 4 from RPA32, and 2 from RPA14 (Table 3-1). The biotinylation patterns and
intensities of the biotinylated peptides were almost identical between the native and hyp-RPA
proteins, except that of the biotinylated peptide of amino acids 340-344 of DBD-B (Figure 3-2,
page 74). This peptide peak was readily detectable in the MS spectra of native RPA, but was
significantly diminished in hyp-RPA (Figure 3-2A, page 74). Figure 3-2B (page 74) is a
representative segment of MALDI-TOF spectra showing that K88 and K379, other 2 of the 24
modified lysines, were biotinylated equally well in both native and hyp-RPA proteins. MS/MS
analysis of the aa 340-344 peptide peak, which exhibited protection in the context of hyp-RPA,
indicated the biotinylation of K343 (Figure 3-2C, page 74). Given that 23 modified lysines
distributed on the surfaces of almost all the domains of RPA trimer, the exhibited similar
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Figure 3-2. Mass spectrometric analysis of relative reactivity of lysines in RPA and hyp-RPA
with NHS-biotin
(A) Representative segment of MALDI-TOF data to show that K343 was readily biotinylated in
native RPA and not in hyp-RPA. (B) MALDI-TOF data illustrate the biotinylated peptide peaks
(aa373-382 and aa82-91) were unchanged in RPA and hyp-RPA. C1-C5 were control peaks that
serve as references for peak intensity. (C) MS/MS analysis of the doubly charged ion 414.70
representing the modified peptide aa340-344 with Q-ToF instrument reveals biotinylated K344.
Left panel shows doubly charged parent ions; right panel shows fragmentation results.
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modification patterns in native and hyp-RPA suggest that no significant global conformational
changes occurred in RPA after hyperphosphorylation. However, the inaccessibility of residue
K343 of RPA70 to NHS-biotin modification in hyp-RPA suggested occurrence of a limited
structural re-arrangement involving the DBD-B domain containing K343 and the
hyperphosphorylated N-terminus of RPA32. Because K343 is located in the DNA-binding cleft
of DBD-B, adjacent to the L12 loop (aa 330-342), it is possible that the hyperphosphorylation
resulted in at least partial shielding of the binding cleft of DBD-B from biotinylation via
intramolecular interactions.

Figure 3-3. MALDI-TOF analysis of arginine modification in RPA and hyp-RPA with HPG
(A) Representative segment of mass spectra to show that R335 and R382 in RPA70 were readily
modified with HPG in native protein but were significantly protected from the modification in
hyper-RPA. (B) Control data to demonstrate that the peak corresponding to the peptide (128138) with R133 modified by HPG in RPA32 of RPA and hyp-RPA remained unchanged.
Unmodified peptide peaks C6 and C7 serve as references for peak intensity.
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We next examined the arginine modifications of RPA and hyp-RPA with HPG. HPG
reacts specifically with the guanidyl group of arginine under mild conditions (pH 7-9, 25 ºC)
resulting in addition of a mass of 131 Daltons to the modified molecule (55). We observed
modification of 18 arginines in the context of native RPA, of which 16 residues were identically
susceptible to modification in hyper-RPA (Table 3-1, page 73). However, the following two
peptide peaks: aa 332-339 (R335 + HPG) and aa 380-389 (R382 + HPG) of RPA70 were
significantly diminished in hyper-RPA (Figure 3-3A, page 75). Figure 3-3B (page 75) depicts
representative segments of MALDI-TOF spectra to show equal intensities of mass signal for the
modifications at R133 of RPA32 in both RPA and hyp-RPA. Residue R335 is located in L12
loop of DBD-B, while R382 at the edge of the DNA-binding cleft of DBD-B adjacent to L45
(7,15). These results are fully consistent with those of biotinylation studies above.

Fluorescence Measurements
RPA has eight tryptophan residues. The locations of the tryptophans are shown in Figure
3-4A (page 77): W197 and W212 in DBD-A, W361 and W414 in DBD-B, W442 and W528 in
DBD-C, W107 in DBD-D, and W2 in the unstructured RPA32N. W212 and W361 have been
shown to be located in the binding clefts of DBD-A and DBD-B, respectively, and to be involved
in the interactions with ssDNA (7). W528 and W107 are located in the putative binding clefts of
DBD-C and DBD-D, respectively, and were predicted to interact with ssDNA (11,12). Indeed,
we previously found that the intrinsic fluorescence of all these in-cleft tryptophans were
quenchable upon ssDNA binding to RPA (unpublished data). If an intramolecular interaction
involving any of the binding clefts occurs in hyp-RPA, the hyperphosphorylation could result in
quenching of the tryptophan fluorescence in the clefts.
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Figure 3-4. Measurements of the intrinsic fluorescence of tryptophans of RPA and its mutants
(A) Structural exhibition of the tryptophans in RPA. The DBDs (16, 18, 21) are positioned by
projecting the ssDNA binding clefts or the putative clefts in the same direction. The tryptophans
of each DBD are marked. (B) Bindings of RPA and its mutants to oligo(dT)30. RPA or the
mutants was incubated with 1 nM (dT)30 at increasing concentrations at 25 ºC for 15 minutes in
20 µL of the binding buffer. The binding products were analyzed on a 4% native polyacrylamide
gel. The positions of the bound and free oligonucleotides are indicated. (C) Emission spectra of
RPA, its mutants, and their hyperphosphorylated forms. The tryptophan fluorescence of the
proteins (100 nM) was recorded from 310 nm to 500 nm at 25 ºC with excitation at 295 nm in
200 µL of RPA buffer. The slit widths were set at 3 and 5 nm for excitation and emission beams,
respectively. All the fluorescence measurement was presented in arbitrary units. (D) Constant
wavelength analyses of RPA, its mutants, and their hyperphosphorylated forms. The intensity of
tryptophan fluorescence of the proteins (100 nM) was recorded at 25 ºC with excitation at 295
nm and emission at 355 nm in 200 µL of RPA buffer. Three data points with an integration time
of 5 seconds and S.E.M. of 0.5% were collected for each measurement. Three measurements for
each sample were performed independently. All the fluorescence measurement was presented in
arbitrary units.

To dissect the roles of individual tryptophans in these interactions we prepared the
following two mutant proteins. The W212/361 protein was obtained by preserving these two
tryptophans and replacing the other 6 tryptophans with phenylalanines. Similarly, in the
W107/528 mutant the residues W107 and W528 were preserved and the other tryptophans were
substituted with phenylalanines. The binding of RPA mutants to ssDNA was tested to ensure that
the mutants were active. Figure 3-4B (page 77) shows that both mutants bound a (dT)30 with an
affinity comparable to that of native RPA, indicating that the substitutions of tryptophans with
phenylalanines had minimum effects on the binding activity of RPA. Then these mutants
together with wild type RPA were subjected to a series of fluorescence measurements. As shown
in Figures 3-4C and D (page 77), the tryptophan fluorescence of the wild type RPA decreased
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upon hyperphosphorylation, suggesting that a structural re-arrangement in hyp-RPA occurred.
However, no fluorescence changes were observed for the W107/528 mutant before and after
hyperphosphorylation. By contrast, about one-half fluorescence was quenched for hypW212/361 (Figures 3-4C and D, page 77), suggesting that one of the two tryptophans was
involved in the structural re-arrangement induced by hyperphosphorylation. Given that W361 is
located in the proximity of K343 and R335 residues that were inaccessible to small chemical
modification in hyp-RPA, we propose that the fluorescence of W361 was quenched due to the
intramolecular interaction involving hyperphosphorylated RPA32N and binding cleft of DBD-B.
The fluorescence quenching for hyp-W212/361 mutant was much more pronounced than that for
wild type RPA. This suggests that more tryptophans in wild type RPA did not exhibit quenching
upon hyperphosphorylation resulting in a higher fluorescence background for the wild type
protein.

Limited Proteolysis of RPA and hyp-RPA
Partial proteolysis could be employed for probing conformational changes of a protein upon
ligand binding or macromolecular interactions via domain mapping (56-58). Because proteolytic
cleavage sites are usually located in the linking regions or loops between domains on the surface
of a protein (59), structural variation of the protein with domain rearrangement may change the
accessibility of some of the cleavage sites, resulting in altered proteolytic profiles. Previously,
proteolytic experiments were carried out to show that RPA changed its conformation upon
binding to ssDNA (56,57) or partial duplex DNA containing a 5’-protruding tail (57). Here we
employed this method to compare the domain structures of native and hyperphosphorylated
RPAs. The two proteins were partially digested with the fixed amount of chymotrypsin for the
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indicated time periods (Figure 3-5, page 81). As shown in Figure 3-5A (page 81), chymotrypsin
digestion revealed several peptide fragments that were more resistant in hyp-RPA compared to
native RPA. Amino acid sequencing enabled us to determine that all these fragments were
resulted from cleavages at the sites located in/near DBD-A and DBD-C of RPA70 (Figure 3-5B,
page 81 and Table 3-2). In other words, these fragments contain no cleavages in DBD-B. Taken
together, these partial hydrolysis data indicated that hyperphosphorylation of RPA32N could
lead to conformational changes in RPA70 and the relatively resistance of DBD-B to partial
proteolysis, which is consistent with the higher resolution results obtained from mass
spectrometric foot-printing and tryptophan fluorescence studies.

Table 3-2. Identification of peptides of RPA or hyp-RPA digested by chymotrypsin
Peptide
fragment
1

Size (kDa)

Origin

51

RPA70

N-terminal sequence
166

GKAAG (major)a
160

2

46

RPA70

213

3

36

RPA70

166

GASKT (minor)a

SNSRG
GKAAG

4

34

RPA70

166

5

20

RPA70

166

GKAAG
GKAAG (major)a
160

GASKT (minor)a

a. N-terminal sequencing gave two different sequences corresponding to two peptide
fragments that migrated at the same position on SDS-PAGE. The amount of one peptide
(major) was larger than the other (minor).
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Figure 3-5. Partial proteolysis of RPA and hyp-RPA with chymotrypsin
(A) 4 µg of RPA or hyp-RPA was digested with chymotrypsin (1:80) at room temperature for the
times indicated. The reactions were then terminated, resolved by 14% SDS-PAGE, and
visualized using SYPRO Ruby stain. Untreated RPA and hyp-RPA were loaded as controls (the
lanes marked as ‘C’). The molecular mass markers are shown on the left. Designations of
individual fragments (dashes) and RPA subunits (arrows) are marked on the right. (B) Schematic
map of proteolytic peptides generated upon RPA or hyp-RPA treatment with chymotrypsin.
Domains are presented as boxes. The cleavage sites of chymotryptic peptide fragments are
roughly shown.
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Bindings of RPA and hyp-RPA to ssDNA and Partial DNA Duplex
How the structural changes of RPA affect its activities may determine the role of RPA
hyperphosphorylation in DNA metabolism. Our previous study showed that the K343 residue in
DBD-B was directly involved in the RPA interaction with ssDNA (41). Because the 8-10 nt
binding mode of RPA-ssDNA interaction has been suggested to be important for the initiation of
replication, replication lagging strand synthesis, and nucleotide excision repair (2,60), here we
examined the bindings of hyp-RPA and RPA to an oligo(dT)8 by gel mobility shift assays
(Figure 3-6A, page 83) and fluorescence anisotropy measurements (Table 3-3, page 85 and
Figure 3-6B, page 83). Both assays revealed that hyp-RPA had a lower affinity for the (dT)8
compared with the native RPA. The anisotropy data were best fitted using a one-site binding
model as described previously (43) and the resulting dissociation constants were 28.9 ± 3.3 nM
and 60.8 ± 3.1 nM for native and hyp-RPAs, respectively. To test whether this affinity change
was specific to DNA sequence, an 8mer ssDNA with random sequences (CATCCTAC) also was
used in our binding assays. Our results indicated similar reduction of the biding affinity for this
DNA species (data not shown).
To examine how hyp-RPA changes its interaction with physiologically relevant DNA
substrates, a set of partial DNA duplexes that mimic in vivo intermediates that occur during DNA
replication and DNA repair was subject to the binding assays. For this purpose, partial DNA
duplexes containing 5’-protruding 11 nucleotides (DNA-11) or 3’-protruding 10 nucleotides
(DNA-10) were constructed. Figure 3-6C (page 83) shows the binding of a mixture of hyp-RPA
and RPA to biotin-labeled DNA-11 and DNA-10 as analyzed by the pull-down assay with
streptavidin-agarose and by Western blotting with an antibody against RPA32.
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Figure 3-6. Bindings of RPA and hyp-RPA to oligo(dT)8 and partial DNA duplexes
(A) RPA was incubated with 1 nM (dT)8 at different molar ratios at 25 ºC for 15 minutes in 20
µL of the binding buffer. The binding products were analyzed on a 4% native polyacrylamide
gel. The positions of bound (dT)8 and free (dT)8 are indicated. (B) 10 nM 5’F-dT8 was titrated
with RPA or hyp-RPA. The anisotropy was measured at 520 nm with excitation at 492 nm. The
binding isotherms were best fitted to obtain the equilibrium dissociation constants (Kd, obs) (44).
(C) Bindings of RPA and hyp-RPA to partial DNA duplexes containing 5’-protruding 11
nucleotides (DNA-11, left) or 3’-protruding 10 nucleotides (DNA-10, right). DNA-11 and DNA10 were constructed by annealing a biotinylated 55mer with its complementary 44mer and
45mer, respectively. The biotinylated partial DNA duplex was incubated with a mixture of RPA
and hyp-RPA. The protein bound to DNA was pulled down with streptavidin beads and detected
by immunoblotting using an antibody against RPA32. The ratio of hyp-RPA to RPA in each
binding was quantified.

The pull-down assay allowed the bindings of RPA and hyp-RPA to ssDNA to be monitored
simultaneously and individually as the two forms of RPA protein were well separated on the
SDS-PAGE. Thus, the binding of native RPA to ssDNA could serve as an internal control for
determination of relative ssDNA binding efficiency of hyp-RPA. As shown in Figure 3-6C (page
83), the hyperphosphorylation led to a significant decrease in binding of RPA to the DNA-11 and
DNA-10 substrates by about 70% and 50%, respectively, demonstrating that hyp-RPA had
significantly lower affinity for these partial DNA duplexes than native RPA.
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Table 3-3. Fluoresecence anisotropy titration of RPA or hyp-RPA binding to 5’F-8mer
hyp-RPA

RPA
Protein (nM)

Mean

Std

Mean

Std

0

0

0

0

0

4

0.0115

0.0010

0.0076

0.0024

8

0.0217

0.0015

0.0147

0.0045

12

0.0367

0.0030

0.0230

0.0025

16

0.0478

0.0025

0.0295

0.0010

20

0.0557

0.0038

0.0335

0.0013

28

0.0627

0.0063

0.0423

0.0017

36

0.0726

0.0042

0.0496

0.0024

44

0.0800

0.0023

0.0564

0.0030

52

0.0906

0.0027

0.0631

0.0029

68

0.0991

0.0034

0.0720

0.0042

84

0.1112

0.0055

0.0778

0.0046

116

0.1126

0.0037

0.0874

0.0039

148

0.1199

0.0040

0.0969

0.0037

212

0.1266

0.0032

0.1098

0.0034

276

0.1289

0.0033

0.1152

0.0028

Mean represents the mean value of three measurements for each titration point;
Std represents the standard deviation.
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Discussion
As a single stranded DNA binding protein in eukaryotic cells, RPA interacts with a large
variety of proteins required for DNA replication, repair, recombination, and DNA damage
checkpoints, suggesting that RPA plays a regulatory role in the cellular DNA metabolic
processes (2,24). In response to DNA damage, RPA undergoes hyperphosphorylation in cells
carried out by the protein kinases of PIKK family (24). The hyperphosphorylation may play a
role in modulating the cellular activities of RPA by altering its ability to interact with DNA and
proteins and is critical to the success of cellular responses to protect against genotoxic stresses.
In the present study, we characterized the structural alterations of RPA upon
hyperphosphorylation by DNA-PK. Our findings provide new and important structural
information regarding the changes introduced in the full length PRA trimer upon
hyperphosphorylation of the protein.
Mass spectrometric foot-printing indicated that several basic residues were surface
inaccessible in DBD-B of RPA 70 upon hyperphosphorylation of RPA32N. Tryptophan
fluorescence studies suggested that W361 located in DBD-B was greatly quenched in response to
hyperphosphorylation. Limited proteolysis revealed the structural changes in RPA70 and the
relative resistance of DBD-B to the proteolytic digestion upon phosphorylation of RPA32N.
Taken together, our findings suggest that a structural re-arrangement involving the RPA32N and
a number of residues in the ssDNA binding cleft of DBD-B occurs after hyperphosphorylation of
RPA (Figure 3-7, page 87). Given that the N-terminus of RPA32 becomes highly acidic (pI was
estimated to be around 2) upon hyperphosphorylation, we propose that this structurally flexible
protein segment of 40 residues could then be electrostatically attracted to the more positively
charged basic region in the DNA binding cleft of DBD-B. This is supported by an estimation that
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the fragment aa 330-345 in the DNA binding cleft of DBD-B, where K343 and R335 are located,
is more basic (pI = ~12) than the equivalent regions of other DBDs.

Figure 3-7. DBD-B structure with highlighted residues
Arg-335, Lys-343, Trp-361 and Arg-382 in brown that could directly interact with
hyperphosphorylated RPA32N. Two loops, Loop12 and Loop45, are indicated in blue. This
figure was drawn based on the RPA70B crystal structure reported by Bochkareva et al. (EMBO
J. 20, 612-618, PDB ID# 1FGU).
A previous NMR study showed that a synthesized acidic peptide mimicking
hyperphosphorylated RPA32N was able to establish electrostatic interactions with the basic cleft
of the purified DBD-F (RPA70N) domain fragment (RPA701-168). However, in the study protein
fragments rather than the full length RPA trimer were used (38). In the context of the full length
protein DBD-B is located closer than DBD-F to interact with hyp-RPA32N. Indeed, based on the
direction of the backbone at amino acid 45 of RPA32 in a crystal structure of RPA trimerization
core (DBD-C/DBD-D/RPA14) unphosphorylated RPA32N was predicted to be located in the
vicinity of the putative ssDNA-binding cleft of DBD-C (11). RPA32N in this position is closer to
DBD-B than to DBD-F, and thus hyperphosphorylation of RPA32N is more likely to have
effects on the closely positioned DBD-B rather than on the more distant DBD-F. Of note, our
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results implicate a possible interaction of DBD-B with RPA32N without major structural
changes in the RPA trimer.
A possible immediate effect of the hyperphosphorylation-induced shielding of the
ssDNA-binding cleft of DBD-B from molecular access on RPA function is the inhibition of RPA
binding to ssDNA, particularly short ssDNA. Indeed, we observed that hyperphosphorylation of
RPA could affect the protein’s ability to bind short oligonucleotides. It has been generally
accepted that RPA binds to ssDNA in three modes in terms of the ssDNA lengths, 8-10 nt, 13-22
nt, and 30 nt, respectively (2,11). Of these modes, the binding to 8-10 nt (2,7,11,61) or short
ssDNA tails of partial DNA duplexes (57,62,63) were exclusively carried out by DBD-A and
DBD-B, while the other two modes required additional domains: DBD-C and DBD-C/DBD-D.
Our results suggest that the potential intramolecular interaction induced by RPA32N
hyperphosphorylation may compete with ssDNA binding to DBD-B. Such competition may
provide a regulatory mechanism for modulating the RPA activities. However, the effect of the
hyperphosphorylation of RPA appeared to be limited to the short ssDNA binding. It has been
generally reported that the dissociation constant for the interaction of RPA with 10 nt or shorter
oligonucleotides was in the order of 10-7 M, while the dissociation constant for the RPA
interaction with ssDNA longer than 15 nt was in the order of 10-10 to 10-9 M (64). Because DBDB is believed to participate in all modes of ssDNA binding, it is likely that the two- to three-order
higher affinity of RPA to longer ssDNA may allow DBD-B to predominately bind ssDNA, so
that the effect of the hyperphosphorylation becomes minimal. Indeed, our results (data not
shown) and also those from others showed that the hyperphosphorylation had negligible effect
on the RPA binding to the ssDNA of 30 nt or longer lengths (20,38).
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In contrast, our results indicate significant competition between hyperphosphorylationelicited DBD-B shielding (probably due to the hyp-RPA32N and DBD-B interaction) and DBDB binding to (dT)8 or partial DNA duplexes with a short ssDNA tail. Such data suggest that the
association constant for the possible intramolecular interaction causing DBD-B shielding could
be in the order of 107 M-1. Interestingly, interactions of RPA with these short ssDNA or partial
DNA duplexes with short ssDNA tails were believed to play a role in the initiation of DNA
replication and replicative lagging strand synthesis (2,38,60,65). Therefore, it is likely that the
hyperphosphorylation of RPA could disrupt this process. Consistently, Vassin et al. (32) recently
reported that a hyperphosphorylation-mimic RPA failed to associate with replication centers in
vivo. Similarly, the DBD-B-engaged intramolecular interactions of RPA due to the
hyperphosphorylation in N-terminus of RPA32 could also affect the RPA-protein interactions
(with dissociation constants in the order of 10-7 M) involved in various DNA metabolic
pathways.
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CHAPTER 4

DNA DAMAGE RESPONSES IN PROGEROID SYNDROMES ARISING FROM
DEFECTIVE MATURATION OF PRELAMIN A

Abstract
The genetic diseases Hutchinson-Gilford progeria syndrome (HGPS) and restrictive
dermopathy (RD) arise from accumulation of farnesylated prelamin A due to defects in the lamin
A maturation pathway. Both of these diseases exhibit symptoms that can be viewed as
accelerated aging. The mechanism by which accumulation of farnesylated prelamin A leads to
these accelerated aging phenotypes is not understood. Here, we present evidence that in HGPS
and RD fibroblasts, DNA damage checkpoints are persistently activated due to the compromise
of genomic integrity. Inactivation of checkpoint kinases ATM and ATR in these patient cells can
partially overcome their early replication arrest. Treatment of patient cells with a protein
farnesyltransferase inhibitor (FTI) did not result in reduction of DNA double strand breaks and
damage checkpoint signaling, although the treatment significantly reversed the aberrant shape of
their nuclei. This suggests that DNA damage accumulation and aberrant nuclear morphology are
independent phenotypes arising from prelamin A accumulation in these progeroid syndromes.
Because DNA damage accumulation is an important contributor to the symptoms of HGPS, our
results call into question on the possibility of treatment of HGPS with FTIs alone.
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Introduction
Hutchinson-Gilford progeria syndrome (HGPS) is a severe childhood disease
characterized by accelerated aging that is caused by a de novo point mutation (1824C → T) in
the LMNA gene that encodes lamin A and the splice variant lamin C and germ cell-specific lamin
C2 (De Sandre-Giovannoli et al., 2003; Eriksson et al., 2003). These lamins are intermediate
filament proteins composing the nuclear lamina, a scaffold underlying the inner nuclear
membrane that structurally supports the nucleus and organizes chromatin (Goldman et al., 2002).
The point mutation (1824C → T) of LMNA results in defective maturation of lamin A from its
precursor prelamin A by causing a deletion of 50 amino acids near the C terminus of prelamin A
that contains an endoprotease (Zmpste 24) cleavage site required for the proteolytic maturation
of lamin A (Eriksson et al., 2003). Zmpste 24 mutation leads to another progeroid disorder,
restrictive dermopathy (RD) that is neonatally lethal (Navarro et al., 2005). Loss of Zmpste 24
activity arrests the processing of prelamin A at a stage similar to HGPS, although a unique
truncated prelamin A (progerin) is accumulated in HGPS cells. Based on the prior elucidation of
the prelamin A processing pathway (Sinensky et al., 1994b), these mutations are predicted to
result in accumulation of farnesylated and carboxymethylated prelamin A. These two diseases
have been suggested to be manifestations of the same cellular problem to different degrees
(Misteli and Scaffidi, 2005). Although the molecular mechanisms by which theses mutations
result in premature aging are far from full understanding, Liu et al. (Liu et al., 2005a) recently
reported that human HGPS fibroblasts and Zmpste24-deficient mouse embryonic fibroblasts
(MEFs) showed increased DNA damage and repair defects. In addition, Varela et al. (Varela et
al., 2005) showed that Zmpste24 deficiency in mouse elicits the upregulation of p53 target genes.
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These studies suggest that the genomic integrity was compromised in HGPS and RD cells due to
the accumulation of progerin and prelamin A, respectively.
Accumulation of DNA damage may activate DNA damage and replication checkpoints
that attenuate cell cycle progression and arrest replication, thereby preventing DNA lesions from
being converted to inheritable mutations (Li and Zou, 2005). Two protein kinases of the
phosphoinositide 3-kinase-like kinase (PIKK) family, ATM and ATR, play the central roles in
initiating the damage and replication checkpoints (Abraham, 2001; Li and Zou, 2005). ATM is
activated primarily in response to DNA double-strand breaks (DSBs) (Shiloh, 2003), whereas
ATR is activated by a broad range of DNA damage and replication interference (Abraham, 2001;
Li and Zou, 2005). Upon activation, ATM and ATR phosphorylate two major signal-transducing
kinases Chk1 and Chk2, which in turn regulate downstream targets, such as Cdc25A, Cdc25C,
and p53, to control cell cycle progression and DNA synthesis (Li and Zou, 2005; Sancar et al.,
2004). It has been reported that in telomere-initiated senescence, a checkpoint response similar to
that in the cells with DNA-damage stress was activated involving ATM, ATR, and downstream
kinases Chk1 and Chk2 (d'Adda di Fagagna et al., 2003; von Zglinicki et al., 2005). Kinase
inactivation experiments showed that this signaling pathway has to be maintained in order to
keep cells in a senescent state (d'Adda di Fagagna et al., 2003; von Zglinicki et al., 2005). DNA
damage accumulation and responses resulting from repair defects may lead to phenotypes
associated with premature aging and may have causal roles in normal aging (Lombard et al.,
2005). Furthermore, evidence has been presented that progerin expression occurs during the
normal aging process (Scaffidi and Misteli, 2006). Given the similarities between these
progeroid syndromes and normal aging, we speculated that the same signaling pathway of DNA
damage response is activated in HGPS and RD cells as in telomere-initiated senescence.
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Several recent studies have shown that inhibition of prelamin A farnesylation by protein
farnesyltransferase inhibitors reversed the aberrant nuclear morphology of progeroid cells
(Capell et al., 2005; Mallampalli et al., 2005; Toth et al., 2005). However, the important question
as to whether treatment with farnesyltransferase inhibitors concurrently restores the genomic
integrity in these cells remains to be addressed.
In this study, we report that DNA damage checkpoints were constantly activated in
HGPS and RD cells due to DNA repair defects. Strikingly, inactivation of ATR and ATM by
specific kinase inhibitor or RNAi partially restored DNA replication in HGPS cells. Also
importantly, treatment of the patient cells with a protein farnesyltransferase inhibitor (FTI) was
found to have no effect on DNA damage in these cells.

Materials and Methods
Cell Culture and Drug Treaments
Fibroblasts from a HGPS patient with the point mutation 1824 C → T were obtained
from the Coriell Cell Repository (no. AG11513A). Human RD fibroblasts were a gift from Dr.
J.H. Miner (Washington University School of Medicine, St Louis, MO). BJ cells and HeLa cells
were purchased from American Type Culture Collection (ATCC, nos. CRL-2522 and CCL-2,
respectively). All cultures were maintained in DMEM (for RD cells and HeLa cells) or EMEM
(for HGPS cells and BJ cells) supplemented with 10% FBS and antibiotics (50 units/ml penicillin
and 50 µg/ml streptomycin) at 37°C under an atmosphere containing 5% CO2. For FTI treatment,
cells were cultured to 70% confluence, and treated with 5 µM FTI L-744832 (Biomol, Plymouth
Meeting, PA) daily for 72 hours before harvest. For the inactivation of ATR and ATM, cells
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were treated with caffeine at a final concentration of 5 mM for at least 2 hours before further
analysis.

Immunofluorescence Microscopy
Cells were grown on coverslips to 70% confluence, washed twice with PBS, and then
fixed with cold methanol (-20ºC) or with 1% formaldehyde followed by permeabilization with
0.5% Triton X-100. The fixed cells were blocked with 15% FBS and then incubated with a
primary antibody against ATR (rabbit or mouse, GeneTex), ATM (mouse, GeneTex), GFP
(rabbit, ABCAM), or γ-H2AX (mouse, Stressgen). After three washes with PBS/1% Tween 20,
the cells were incubated with a secondary antibody Alexa fluor 488-conjugated donkey antirabbit IgG or Alexa fluor 568-conjugated goat anti-mouse IgG (Molecular Probes). Nuclei were
counterstained with DAPI. Cells were visualized by using a Zeiss Axioscope microscope.

Transfection of Plasmids and siRNA
HeLa cells grown on coverslips were transiently transfected with plasmid pEGFPLA∆50, pEGFP-LA∆50-SSIM (both were gifts from Dr. Francis Collins, NIH), control plasmid
pEGFP, or empty parent vector using GeneJammer transfection reagent (Stratagene) following
manufacture’s instruction. Twenty-four hours post-transfection, the cells were processed
differently for the following experiments. For examining the activation of ATM and ATR, the
cells were irradiated with 20 J/m2 UV or mock treated. Two hours post-treatment, the cells were
processed for immunofluorescence microscopy as described above. To measure the amount of γH2AX, the cells were harvested and lysed for Western blotting as described below. For detecting
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the formation of γ-H2AX foci, the cells were fixed with 1% formaldehyde and processed for
immunofluorescence.
For the knockdown of ATR and ATM by RNAi, the cells were transfected with ATR
siRNA and ATM siRNA (Wu et al., 2006), or GFP siRNA as a control using TransIT-TKO
transfection reagent (Mirus) following manufacture’s instruction. Further analyses were
performed 72 hours after transfection.

DNA Synthesis Assay
DNA synthesis was assayed by the method of thymidine incorporation modified from
Shao et al. (Shao et al., 1997). Briefly, 2 x 105 cells were seeded in a 35-mm dish 24 hours
before pulse-labeling with 0.5 µCi/ml [methyl-3H]thymidine (Amersham Biosciences) for 30
minutes. The cells were then rinsed with PBS three times and harvested by lysis with 5%
trichloroacetic acid (TCA) at 4 ºC for 1 hour. Cell lysates were subjected to filtering using
Whatman glass microfibre filters and a vacuum manifold. The filters were washed twice with 5
ml of 5% TCA, once with 70% ethanol, and then dried. The radioactivity of each sample was
counted by liquid scintillation.

Western Blotting
Cells cultured in 100-mm dishes were grown to 70% confluence and then trypsinized.
Cell number was counted by using a hemacytometer. The cells were centrifuged at 1500 rpm for
5 minutes and washed twice with PBS. Cell pellet was lysed in 2 x SDS gel loading buffer and
volumes corresponding to 5 x 106 cells were subjected to SDS-PAGE. Immunoblotting was
carried out as previously described (Liu et al., 2005b) with primary antibodies directed against
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p53 (Santa Cruz), p53 (ser-15) (Cell Signaling), Chk2 (thr-68) (Cell Signaling), Chk1 (ser-345)
(Santa Cruz), γ-H2AX (Bethyl), GAPDH (Santa Cruz), LaminA/C (Santa Cruz), and β-actin
(Santa Cruz). The rabbit anti-mouse prelamin A antiserum used was generated specifically
against the carboxyl-terminal prelamin A and cannot bind mature lamin A or lamin C (Sinensky
et al., 1994a).

Comet Assay
The neutral comet assay was performed to assess DNA strand breaks in cells. The first
layer of agarose on microscope slides were prepared by dipping the slides into 1% normal
melting point agarose (NMA) followed by drying. Eighty-five microliters of 0.5% low melting
point agarose (LMA) containing 4 × 105 cells was made by mixing 10 µl of cell suspension with
75 µl of LMA. The mixture was then poured onto the pre-coated slides. Slides were immersed in
freshly prepared ice-cold buffer (2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris–HCl, 1% Triton
X-100, pH 10) to lyse the cells for at least 1 hour at 4 °C in the dark. The slides were then placed
in the alkaline buffer (0.3 M NaOH, 1 mM EDTA, pH > 13) for 30 minutes for DNA unwinding.
The slides were equilibrated in TBE buffer for 5 minutes twice followed by electrophoresis at 1
volt/cm in TBE buffer for 10 minutes. The slides were then dipped in 70% ethanol for 5 minutes
and dried at room temperature for 1 hour. Fifty microliters of 600 µM DAPI was used for
staining. All steps described above were conducted under dimmed light to prevent additional
DNA damage. The quantification of the comets was conducted for randomly chosen 50 cells, and
DNA damage was expressed as the percentage of DNA in tail.
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Results
Early Replication Arrest of RD Cells and HGPS Cells
Results from our studies (Figure 4-3, page 105) and others (Liu et al., 2005a; Varela et
al., 2005) showed that a considerable amount of phosphorylated histone H2AX (γ-H2AX), a
molecular marker for DNA double-strand breaks (DSBs) (Sedelnikova et al., 2002), formed in
HGPS and RD cells. This indicates that DNA damage accumulates in patient cells. To determine
the status of DNA replication in these cells, a DNA replication assay with replicative
incorporation of [methyl-3H] thymidine was performed. As shown in Figure 4-1,

Figure 4-1. Early replication arrest of HGPS and RD cells
The replication assay was carried out with [methyl-3H] thymidine labeling as described in
Materials and Methods. Symbols represent radioactivity values as follows: ● for BJ cells; ○ for
HGPS cells; and ▼ for RD cells. The values were calculated from three independent
experiments. Error bars represent standard deviations.

DNA synthesis in the HGPS and RD cells of passage 11 occurred at rates more than 2-fold
slower than that in BJ cells, a non-transformed human diploid fibroblast cell line. Moreover,
replicative capacity was lost at passage 15 for RD cells and at passage 21 for HGPS cells (Figure
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4-1, page 101) in contrast to the more typical replicative behavior of BJ cells that exhibit many
more passages before undergoing replicative senescence (Steinert et al., 2000). This premature
replicative senescence of the patient cells is consistent with the previous reports that the
percentage of S-phase cells in Zmpste24-deficient mouse embryonic fibroblasts (MEFs) was
lower than that in normal MEFs (Liu et al., 2005a; Varela et al., 2005).

Activation of ATM and ATR in RD Cells and HGPS Cells
The premature replicative senescence of HGPS and RD cells suggested that G1/S
and/or intra-S checkpoints were likely activated. To test this notion, we assessed the activation of
ATM and ATR, two central initiators of DNA damage checkpoints (McGowan and Russell,
2004), in HGPS and RD cells using the method of immunofluorescence microscopy. In BJ cells,
the majority of ATM was homogenously distributed in the nucleus (Figure 4-2A, page 104). The
treatment of BJ cells with camptothecin (CPT), a radiomimetic agent widely used to induce
DSBs and activate ATM in cells (Shiloh, 2003), caused ATM focus formation in the nuclei
(Figure 4-2A, page 104). Interestingly, a very similar pattern of ATM nuclear focus formation
was observed in HGPS and RD cells even without treatment with CPT, suggesting that ATM
was activated in these cells (Figure 4-2A, page 104). By contrast, a different pattern of activation
was observed for ATR in these patient cells. In unstressed BJ cells, ATR was mainly localized in
cytoplasm, with little or no nuclear staining (Figure 4-2B, page 104). After UV irradiation, a
known DNA damaging stress that induces ATR activation (Abraham, 2001), ATR translocated
from cytoplasm into the nucleus. Interestingly, while the majority of ATR was in the nuclei of
untreated RD cells, only part of ATR was distributed in the nuclei of HGPS cells and formed
large foci or aggregates (Figure 4-2B, page 104). The nuclear distribution of ATR in RD and
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HGPS cells suggests its activation in these cells, which is confirmed by the phosphorylation of
its primary substrate Chk1 (see below). To verify that nuclear translocation of checkpoint kinases
in the patient cells arises from expression of prelamin A, HeLa cells were transfected with a
plasmid encoding progerin (LA∆50) for immunofluorescence analysis. As shown in Figure 4-2C
(page 104), the majority of ATR was in cytoplasm in HeLa cells transfected with an empty
parent vector. In contrast, ATR was mainly located in nuclei, forming large foci in the HeLa
cells transfected with the LA∆50-expression plasmid. This indicated that the nuclear
translocation of checkpoint kinases was indeed induced by the presence of progerin. Thus, DNA
damage in HGPS and RD cells, arising from prelamin A accumulation, results in nuclear
redistribution of ATR and ATM, consistent with activation of cell cycle checkpoints.
To confirm the presence of checkpoint response pathways in HGPS and RD cells, we
next examined the activation of downstream signal-tranducers Chk1 and Chk2 and the effector
p53 by assessing their phosphorylation status at specific sites (Helt, 2005). As shown in Figure
4-3 (page 105), besides phosphorylation of H2AX, phosphorylation of Chk1 (Ser-345), Chk2
(Thr-68), and p53 (Ser-15) were all readily detected in HGPS and RD cells, confirming the
activation and signaling of checkpoint pathways in these cells.
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Figure 4-2. Activation of ATM and ATR in HGPS and RD cells
(A) CPT treatment was done by incubating the cells with 4 µM camptothecin for 1 hour. Cells
with or without treatment were fixed with cold methanol (-20ºC) followed by
immunofluorescence microscopy with ATM antibody staining. Blue, DAPI; red, ATM. (B) UV
treatment was carried out by irradiating the cells with 20 J/m2 UV. Two hours after the treatment,
the cells with or without treatment were fixed and stained with ATR antibody for
immunofluorescence microscopy. Blue, DAPI; red, ATR. (C) HeLa cells grown on coverslips
were transfected with the plasmid for expressing progerin (LA∆50) or empty parent vector.
Twenty-four hours after transfection, the cells were irradiated with 20 J/m2 UV or mock treated.
After additional 2-hour culture, the cells were processed for immunofluorescence microscopy.
Blue DAPI; green or red, ATR. Photomicrographs were taken at x63 magnification. Scale bar, 50
µm.

Figure 4-3. Phosphorylation of Chk1, Chk2, and p53 in HGPS and RD cells
Western blotting was performed as described in Materials and Methods. The phosphorylation
status of p53 was determined with p53 Ser-15 phosphorylation-specific antibody. The total p53
was probed as the loading control to ensure that the same amounts of p53 were loaded for BJ,
RD, and HGPS cells. In the right panel, β-actin was probed to ensure that similar amounts of
proteins were loaded for the three cell lines.
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Restoration of Replication Activity by Inactivation of ATM and ATR
DNA damage checkpoint responses are complex signaling pathways orchestrated by the
PIKK family including ATM and ATR (Abraham, 2001). Cells with deficient ATM and/or ATR
are defective in initiating DNA damage-induced cell-cycle arrest (Shiloh, 2003). To test whether
inactivation of ATM and ATR could abolish the premature senescence observed in the patient
cells, we treated cells with 5 mM caffeine, an ATM and ATR inhibitor (Sarkaria et al., 1999),
and measured their DNA synthesis by [methyl-3H] thymidine labeling. As shown in Figure 4-4A
(page 107), both ATM and ATR were efficiently knocked down in BJ and HGPS cells
transfected with ATR and ATM siRNAs. The observation of lower cellular levels of ATM and
ATR in GFP siRNA-transfected HGPS cells than their levels in corresponding BJ cells could be
due to the tight chromatin association of ATM and ATR in the checkpoint-activated HGPS cells.
These proteins could be partially resistant to extraction for Western blot analysis. However,
regardless of the basis for the lowered levels of ATM and ATR in the controls, a relative
knockdown by the siRNAs was observed. As shown in Figure 4-4B (page 107), the knockdown
significantly increased DNA synthesis in HGPS cells while having no obvious effect on that of
the control BJ cells. Similar data were produced by treating the cells with caffeine (Figure 4-4B,
page 107). These results confirm that DNA damage checkpoints were activated in the patient
cells and demonstrate that the replicative senescence of these patient cells can be reversed by
inactivation of checkpoint kinases.
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A

B

Figure 4-4. Restoration of replication activity in HGPS cells by inactivation of ATM and ATR
(A) Western blotting shows the knockdown of ATR and ATM in BJ and HGPS cells by RNAi.
β-actin was used as sample loading control. (B) The replication assay was carried out with
[methyl-3H] thymidine labeling as described in Materials and Methods. BJ cells and HGPS cells
used were at passage 12. The symbol * indicates a significant difference between HGPS with
treatment and HGPS with mock treatment, P < 0.05.
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FTI Treatment, A Potential Therapy for HGPS and RD?
Recent studies showed that FTI treatment can correct aberrant nuclear morphology in
HGPS fibroblasts (Capell et al., 2005; Mallampalli et al., 2005; Toth et al., 2005) and RD
fibroblasts (Toth et al., 2005). FTI treatment also ameliorates disease phenotypes in Zmpste24deficient mice (Fong et al., 2006). Because DNA damage accumulation is believed to be one of
the major causes of accelerated aging, cellular senescence and normal aging (d'Adda di Fagagna
et al., 2003; Gorbunova and Seluanov, 2005; Kirkwood, 2005; Lees-Miller, 2005; Lombard et
al., 2005; Misteli and Scaffidi, 2005; von Zglinicki et al., 2005), it is of great interest to test
whether FTIs also can reduce the accumulated DNA damage in these cells. As shown in Figure
4-5A (page 110), treatment of HGPS and RD fibroblasts of passage 15 with L-744832, a potent
FTI (Capell et al., 2005), significantly reduced the percentage of cells with misshapen nuclei
(from 47% to 11% for RD cells, P < 0.005; from 33% to 6% for HGPS cells, P < 0.001). The
misshapen nuclei were defined as nuclei with blebs, folds, or gross irregularities in shape (Toth
et al., 2005), and the counting was carried out by two observers who randomly chose 200 cells
from each experiment group. This result confirms that FTI treatment can normalize the nuclear
morphology of the patient cells. Consistent with these results, FTI treatment of BJ and HGPS
fibroblasts caused accumulation of prelamin A in these cells as analyzed by Western blotting
(Figure 4-5B, page 110) with prelamin A specific antibody (Sinensky et al., 1994a),
demonstrating the efficacy of the FTI in blocking farnesylation in cells. By contrast, however, no
substantial reduction of DSBs was detected in HGPS and RD cells after FTI treatment, as
evidenced by the amount of γ-H2AX analyzed by Western blotting (Figure 4-5B, page 110). The
same HGPS cells were also subjected to single cell gel (SCG) electrophoresis or comet assays
that directly measured the DSBs in cells. As shown in Figure 4-5C (page 110), there was no
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substantial difference in the amount of DNA damage generated in the cells with and without FTI
treatments. In addition, ATM and ATR damage checkpoint signaling was also examined. As
shown in Figure 4-5D (page 110), both the checkpoint substrates, Chk1 and Chk2, of ATR and
ATM were well phosphorylated in FTI treated and untreated HGPS cells, indicating their
activation. Importantly, the phosphorylation was equally efficient in the cells with or without FTI
treatment. These observations indicated that FTI treatment was unable to reduce the accumulated
DNA damage in these cells despite its capacity to improve the nuclear morphology.
To further confirm the results, pEGFP-LA∆50 and pEGFP-LA∆50-SIIM plasmid
constructs, respectively, were transfected into HeLa cells. pEGFP-LA∆50-SIIM is a construct for
expression of the LA∆50 with a mutation at its farnesylation site, making the progerin
prenylation-incompetent (Capell et al., 2005). Unlike FTI treatment that may not be able to
completely abolish the farnesylation of progerin, expression of pEGFP-LA∆50-SIIM produces
only the unfarnesylated LA∆50. As shown in Figure 4-5E (page 110), the expression of LA∆50
and prenylation incompetent LA∆50-SSIM in HeLa cells induced similar levels of γ-H2AX
accumulation, indicating that farnesylation had no substantial effect on the cellular DNA damage
accumulation induced by progerin. This is consistent with the above results obtained with HGPS
cells. Our results also suggested that DNA damage accumulation and misshapen nuclei are
perhaps two independent phenotypes produced by prelamin A accumulation in HGPS and RD.
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Figure 4-5. FTI treatment of HGPS and RD cells
(A) Improvement of nuclear shapes of HGPS and RD cells by FTI treatment. The patient cells
were treated with FTI and prepared for immunofluorescence microscopy as described in
Materials and Methods. The nuclei were stained with DAPI. Misshapen nuclei were indicated by
arrows. Photomicrographs were taken at x63 magnification. Scale bar, 50 µm. (B) FTI treatment
blocked farnesylation of prelamin A but did not change the production of γ-H2AX, a molecular
marker for DSBs. In the left panel, BJ and HGPS cells were lysed in 2 x SDS gel loading buffer
and probed with the antibody directed against prelamin A. In the right panel, HGPS and RD cells
were lysed and probed with the antibody for γ-H2AX. β-actin was loaded to ensure similar
amounts of samples were used for each pair of experiment groups. (C) Comet assays were
carried out with HGPS cells in the presence and absence of FTI as described in Materials and
Methods. DSBs of 50 randomly chosen cells were quantitated as the percentage of DNA in tail.
(D) Phosphorylation of Chk1 and Chk2 in HGPS cells with or without FTI treatment. The FTI
treatment of BJ and HGPS and Western blotting were performed as described in Materials and
Methods. The phosphorylation statuses of Chk1 at Ser-345 and Chk2 at Thr-68 were determined
with corresponding antibodies. β-actin was probed as a loading control. (E) Accumulation of γH2AX in cells expressing prelamin A mutants. HeLa cells were transfected with plasmid
pEGFP, pEGFP-LA∆50, or pEGFP-LA∆50-SSIM, followed by Western blot analysis. GAPDH
was probed as a loading control.

Discussion
DNA damage is believed to contribute to both aging and cellular senescence (Lombard et
al., 2005) that has been regarded as a permanently maintained DNA damage response state (von
Zglinicki et al., 2005). Defects in several DNA repair proteins lead to DNA damage
accumulation and damage responses that cause phenotypes reminiscent of premature ageing
(Lombard et al., 2005). As there is no evidence for any mutations in DNA repair genes in HGPS
and RD cells, we, and others, hypothesize that prelamin A accumulation affects DNA repair in
these syndromes. In this study, we present direct evidence that DNA damage checkpoints were
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constantly activated in HGPS and RD cells due to accumulated DNA damage. We also
demonstrated that the subcellular distribution of checkpoint kinases ATM and ATR may be used
as an indicator for their activation in vivo. Inactive ATM is homogenously distributed in the
nucleus, while nuclear focus formation of ATM indicates its activation. In unstressed cells, ATR
is mainly localized in cytosol but translocates into the nucleus upon DNA damaging stress such
as UV irradiation. Our finding is contradictory to that of Manju et al. (Manju et al., 2006) who
recently reported that ATR was normally localized in the nucleus. The explanation for this
discrepancy may lie in the fact that FLAG-ATR was ectopically expressed in cells in the Manju
et al. study, while we used normal cells and stained endogenous ATR directly. The expression of
exogenous proteins likely induces stress to the cells, which may cause the translocation of ATR
from cytosol to the nucleus. In the present study, activation of ATR and ATM in the patient cells
as evidenced by immunofluorescence determination was confirmed by the phosphorylation of
their downstream substrates Chk1, Chk2, and p53 as analyzed by Western blotting.
Interestingly, inactivation of ATM and ATR in HGPS cells partially restored cell-cycle
progression into S phase. This confirms that a form of prelamin A (progerin) activated DNA
damage responses, leading to replicative senescence. Importantly, this senescence can be
suppressed by inactivating DNA damage response pathways in HGPS cells. That only partial
restoration of S-phase progression is observed is likely due to the incomplete repression of the
DNA damage responses as even a residual kinase activity could be sufficient to enforce a DNA
damage checkpoint (Cortez et al., 2001). Varela et al. showed that p53 knockout completely
recovered the proliferative capacity of Zmpste24-/- mouse cells (Varela et al., 2005). We expect
that a highly efficient checkpoint inhibition would permit a significant recovery of cell division
and alleviate many other senescence-associated phenotypes in progeroid cells.
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Aberrant nuclear morphology is the most obvious phenotype caused by prelamin A
accumulation in HGPS and RD fibroblasts (Goldman et al., 2004; Toth et al., 2005). Recent
studies showed that FTI treatment could correct the nuclear morphology defects of progeroid
cells (Capell et al., 2005; Glynn and Glover, 2005; Mallampalli et al., 2005; Toth et al., 2005).
However, we found that FTI treatment could not reduce the accumulated DSBs in both HGPS
and RD cells. This suggests that DNA damage accumulation and misshapen nuclei are probably
two unrelated phenotypes caused by prelamin A accumulation in HGPS and RD. Consistent with
this notion, p53 knockout can restore proliferative capacity of Zmpste24-/- mouse cells but only
partially reverse other disease phenotypes (Varela et al., 2005), suggesting that independent
pathological pathways exist and cooperate with each other in the generation of progeroid
phenotypes. Thus, strategies for treatment of HGPS need to combine elimination of DNA
damage accumulation as well as normalization of nuclear morphology.
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CHAPTER 5

XERODERMA PIGMENTOSUM GROUP A (XPA) INHIBITS REPAIR OF DNA DOUBLESTRAND BREAKS IN LAMINOPATHY-BASED PREMATURE AGING CELLS

Abstract
Cellular accumulation of DNA damage has been widely implicated in cellular
senescence, aging, and premature aging. In Hutchinson-Gilford progeria syndrome (HGPS) and
restrictive dermopathy (RD), premature aging is linked to accumulation of DNA double-strand
breaks (DSBs) that results in genome instability. However, how DSBs accumulate in cells
despite the presence of intact DNA repair proteins remains unknown. Here we report that the
recruitment of DSB repair factors Rad50 and Rad51 to the laminopathy-related DSB sites, as
marked by γ-H2AX, was impaired in human HGPS cells and Zmpste24-deficient cells, making
the DSBs unrepairable. By contrast, a significant amount of nuclear foci of XPA, a unique
nucleotide excision repair protein, formed in the progeroid cells even without DNA damage
agent treatment. Strikingly, these foci massively colocalized with the unrepairable laminopathyinduced DSBs but not to the repairable DSBs induced by camptothecin. RNAi knockdown of
XPA in HGPS cells significantly restored DSB repair as evidenced by Western blot analysis,
immunofluorescence, and comet assays. Our results suggest that the uncharacteristic localization
of XPA to DSBs may inhibit DSB repair in the progeroid cells so that XPA dysfunction may
play an important role in accumulating DSBs for development of progeroid laminopathies. Our
results also provide a potential strategy for treatment of these devastating premature aging
diseases.
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Introduction
Hutchinson-Gilford progeria syndrome (HGPS) is a dominant premature aging disease
caused by formation of a carboxyl-terminal truncated form (progerin) of the lamin A precursor,
prelamin A (De Sandre-Giovannoli et al., 2003; Eriksson et al., 2003). Lamin A is an
intermediate filament protein in the nuclear lamina, a scaffold underlying the inner nuclear
membrane that structurally supports the nucleus and organizes chromatin (Goldman et al., 2002).
Homozygous deficiency of Zmpste24, an endoproteinase essential for the proteolytic maturation
of prelamin A, results in restrictive dermopathy (RD), which is a lethal perinatal progeroid
disorder (Navarro et al., 2005). Loss of Zmpste 24 proteinase activity arrests the processing of
prelamin A at a stage similar to HGPS, although progerin instead of prelamin A is accumulated
in HGPS cells. These two diseases have been suggested to be manifestations of the same cellular
problem to different degrees (Misteli and Scaffidi, 2005).
It has been recently shown that HGPS and RD cells exhibit DSB accumulation,
impairment of DNA repair, and activation of the p53-dependent stress signaling pathway (Liu et
al., 2005; Manju et al., 2006; Varela et al., 2005), suggesting that genome instability caused by
HGPS and RD might contribute to premature aging. The DSB accumulation in HGPS and
Zmpste24-deficient cells as well as in senescing and aging mammalian cells appears to be due to
unrepairable DSBs (Sedelnikova et al., 2004). However, the underlying mechanism of the repair
defect is still poorly understood. We asked the question of how DNA repair is compromised in
HGPS and RD cells even though there is no evidence of mutations in repair genes.
In the present study, using immunofluorescence microscopy and chromatin
immunoprecipitation (ChIP) assay, we examined the localization of DNA repair proteins in
relation to γ-H2AX, a molecular marker for DSBs, in the progeroid cells. We found that DSB
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repair proteins Rad51 and Rad50 were not localized to the DNA damage sites, while XPA, a
unique nucleotide excision repair protein, largely colocalized with the DSBs formed due to
laminopathies in HGPS and RD cells. This suggests that the mislocalization of XPA to DSBs
may be responsible for the unrepairability of laminopathy-phenotyped DNA damage in the
progeria cells. In support, RNAi knockdown of XPA in HGPS cells significantly restored DSB
repair. We speculated that XPA dysfunction may play an important role in the development of
progeroid laminopathies.

Materials and Methods
Cell Cultures
Fibroblasts from a HGPS patient with the point mutation of 1824C → T were obtained
from Coriell Cell Repository (no. AG11513A). Human RD fibroblasts were a gift from Dr. J.H.
Miner (Washington University School of Medicine, St Louis, MO). The normal human
fibroblasts, BJ cells, were purchased from American Type Culture Collection (ATCC, no. CRL2522). All cultures were maintained in DMEM (for RD cells) or EMEM (for HGPS and BJ cells)
supplemented with 10% FBS and antibiotics.

Immunofluorescence Microscopy
Cells grown on coverslips were fixed with cold methanol (-20ºC) or extracted with 0.5%
IGEPAL CA-630 followed by fixation with methanol. The fixed cells were then incubated with
primary antibodies against γ-H2AX (rabbit, Bethyl; or mouse, Stressgen), XPA (mouse, Kamiya;
or rabbit, Santa Cruz), Rad51 (rabbit, Santa Cruz), Rad50 (rabbit, Bethyl), and XPC (rabbit,
GeneTex). Secondary antibodies used include Alexa fluor 488-conjugated donkey anti-rabbit
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IgG and Alexa fluor 568-conjugated goat anti-mouse IgG (Molecular Probes). Cells were
counterstained with DAPI to visualize nuclear DNA. Focus counting was performed by two
blinded observers who randomly chose 50 cells for each experiment.

Western Blotting
For immunoblotting of XPA and lamin proteins, whole-cell extracts were prepared from
~107 cells. The samples were separated by SDS-PAGE and immunoblotted with antibodies
against XPA (GeneTex), prelamin A (Sinensky et al., 1994) or lamin A/C (Santa Cruz), or βactin (Santa Cruz).

γ-H2AX Association Assay and Co-Immunoprecipitation
The γ-H2AX association assay used in this study was modified from the histone
association assay described by Ricke et al. (Ricke and Bielinsky, 2005). Briefly, cells were
treated with formaldehyde to crosslink interacting protein-DNA as well as protein-protein
complexes. Nuclei were prepared by fractionation. The chromatin was sheared into 200-1500 bp
fragments by sonication. The sheared chromatin was incubated with γ-H2AX antibody, followed
by precipitation with protein G Sepharose beads. The immunoprecipitates were boiled for at least
30 minutes to reverse the crosslinks (Ricke and Bielinsky, 2005). Proteins that co-precipitate
with chromatin were detected by Western blotting.
The co-immunoprecipitation was performed using a Nuclear Complex Co-IP kit (Active
Motif, CA), following the manufacture’s instructions.
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Comet Assay
The neutral comet assay was performed to assess DNA strand breaks in cells. The first
layer of agarose on microscope slides were prepared by dipping the slides into 1% normal
melting point agarose (NMA) followed by drying. Eighty-five microliters of 0.5% low melting
point agarose (LMA) containing 4 × 105 cells was made by mixing 10 µl of cell suspension with
75 µl of LMA. The mixture was then poured onto the pre-coated slides. Slides were immersed in
freshly prepared ice-cold buffer (2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris–HCl, 1% Triton
X-100, pH 10) to lyse the cells for at least 1 hour at 4 °C in the dark. The slides were then placed
in the alkaline buffer (0.3 M NaOH, 1 mM EDTA, pH > 13) for 30 minutes for DNA unwinding.
The slides were equilibrated in TBE buffer for 5 minutes twice followed by electrophoresis at 1
volt/cm in TBE buffer for 10 minutes. The slides were then dipped in 70% ethanol for 5 minutes
and dried at room temperature for 1 hour. Fifty microliters of 600 µM DAPI was used for
staining. All steps described above were conducted under dimmed light to prevent additional
DNA damage. The quantification of the comets was conducted for randomly chosen 50 cells, and
DNA damage was expressed as the percentage of DNA in tail.

Results
Accumulation of DSBs in HGPS Cells and RD Cells
We first examined accumulation of DSBs in HGPS and RD fibroblasts by probing γH2AX focus formation using immunofluorescence (IF) microscopy. The normal human diploid
fibroblasts, BJ cells, were used here as a control. The expression of wild-type prelamin A and/or
progerin in HGPS and RD cells or normal lamin A in BJ cells was confirmed by Western
blotting (Figure 5-1a, page 123). By using IF, we observed γ-H2AX foci in approximately 61%
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RD cells and 53% HGPS cells (passage 16), but only in about 8% BJ cells at the same passage.
The number of γ-H2AX foci in RD (13.8±3.3 per cell) and HGPS fibroblasts (10.5±3.0 per cell)
was significantly higher than that in the control BJ fibroblasts (0.4±0.3 per cell) (Figure 5-1b,
page 123). Although γ-H2AX foci were also observed in human M-phase cells in the absence of

Figure 5-1. Prelamin A and DSB accumulation in BJ, HGPS and RD fibroblasts
(a) Western blot analysis of prelamin A. Cells were grown for the indicated number of passages,
and Western blot analyses of cell extracts were performed with antibodies specific for: Top,
prelamin A, (specific for the extreme C terminus) and Bottom, lamin A/C (binds to both lamin A
and lamin C). Symbols indicate the following: (*) = Prelamin A, (o) = mature Lamin A, (-) =
LA∆50 and (+) = Lamin C. (b) DSB formation as revealed by γ-H2AX foci. Cells were stained
with anti-γ-H2AX antibody. Blue, DAPI; green, γ-H2AX. The percentage of cells containing γH2AX foci is shown on the left bottom of each subpanel; the number of γ-H2AX foci per cell is
shown on the right bottom.
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DSBs and DNA damage signaling (Ichijima et al., 2005), these foci were locally condensed in
nuclei and the pattern/type was very different from that of the DSBs-induced discrete foci
formed throughout the whole nuclei (Ichijima et al., 2005). In the present study, only discrete
foci have been considered. Importantly, our control BJ cells that had similar percentage (2530%) of G2/M-phase population as HGPS and RD cells (data not shown and refs. (Liu et al.,
2005; Varela et al., 2005)) showed little discrete focus formation as compared to that of progeria
cells. In HGPS and RD cells, discrete γ-H2AX foci appeared in more than half of the population.
Furthermore, direct evidence from comet assays confirmed that more than half of HGPS cells
had DSBs (Figure 5-6c, page 132). The DSBs in HGPS and RD cells were also confirmed by the
activated DNA damage responses in these progeria cells involving ATM, ATR, and downstream
phosphor-kinases Chk1 and Chk2 (Chapter 4). The significant increase of γ-H2AX foci in lamin
A-defective cells indicates that defects in lamin A maturation is correlated with DSB formation
in cells.

Mislocalization of DSB Repair Proteins and Colocalization of XPA with DSBs
In an effort to determine the mechanism by which DSBs are resistant to being repaired
and thus accumulate in HGPS and RD cells, we examined the nuclear localization of several
DNA repair proteins. We found that the HGPS and RD cells showing γ-H2AX foci also
contained foci of the DSB repair protein Rad51 (Figure 5-2a, page 125). The massive fluorescent
staining of Rad51 in HGPS and RD cells indicates that some Rad51 protein may aggregate in the
patient cells. However, colocalization of Rad51 and γ-H2AX was random (only about 5% and
2% for RD and HGPS cells, respectively) (Figure 5-2a, page 125). This suggests that Rad51 was
unable to localize to the DSB sites for DNA damage repair. In contrast, discrete Rad51 foci were
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Figure 5-2. Colocalization of γ-H2AX foci and the foci of DNA repair proteins in BJ, HGPS and
RD fibroblasts
Nuclear focus localization of Rad51 (a), Rad50 (b), XPA (c and e), and XPC (d) relative to γH2AX foci were detected with corresponding antibodies by immunofluorescence microscopy.
Uniform staining of the given protein throughout nucleus indicates homogenous distribution of
the protein without foci formation. CPT treatment of cells was conducted by incubating the cells
with 4 µM CPT for 1 hour before fixation. The green foci in the Merge subpanel of (e) represent
the CPT-induced DSBs (arrows) that were not colocalized with XPA foci. The nucleus is
visualized by DAPI staining.
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Figure 5-3. Specificity of human XPA antibodies used in this study
(a) Western blot analysis of whole cell extracts by human XPA antibody (mouse, Kamiya). The
XPA was visualized as a doublet of bands. (b) Formation of XPA foci in HGPS cells identified
by human XPA antibody raised from rabbits (Santa Cruz).
formed and perfectly colocalized with DSBs as marked by γ-H2AX foci in BJ cells treated with
camptothecin (CPT), a DSBs inducer (Figure 5-2a, page 125). The same results were also
obtained with Rad50 (Figure 5-2b, page 125), a subunit of Mre11/Rad50/Nbs1 (MRN) complex
involved in DSB damage signaling and repair (Lee and Paull, 2004; Lee and Paull, 2005; Paull
and Lee, 2005; Sancar et al., 2004). These results suggest that the defective repair of DSBs in
HGPS and RD fibroblasts is probably due to a disruption of recruitment of DSB repair factors
such as MRN and Rad51 to the damage sites.
Our further investigation led to a surprising finding that xeroderma pigmentosum group
A (XPA), a unique nucleotide excision repair (NER) factor, formed a large number of nuclear
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foci in HGPS and RD cells. Strikingly, these foci colocalized almost completely with γ-H2AX
foci (Figure 5-2c, page 125). Specificity of the human XPA antibody (mouse) used in the
detection was confirmed by Western blotting of whole cell extracts and by the similar
immunofluorescence measurement with different XPA antibody (rabbit) from a different
company (Santa Cruz) (Figure 5-3, page 126). The specificity was also verified by the siRNA
knockdown experiments (Figure 5-6a, page 132). By contrast, other NER proteins, XPC
(xeroderma pigmentosum group C), and RPA (replication protein A), showed no focus formation
in HGPS and RD cells (Figure 5-2d, page 125, and data not shown). XPA and XPC are DNA
damage-recognition proteins in NER and have no role in DSB repair (Sancar et al., 2004). RPA
also is a DNA damage recognition protein and the main single-stranded DNA (ssDNA) binding
protein in human cells (Zou et al., 2006).These results suggest that the colocalization of XPA and
γ-H2AX was specific and NER-unrelated. This is consistent with the specificity of NER that
neither processes DSBs nor generates DSB intermediates (Sancar et al., 2004). As shown in
Figure 5-2e (page 125), evidence that further supports the specificity of XPA-γ-H2AX
colocalization in HGPS and RD cells came from the observation that XPA did not colocalize
with CPT-induced γ-H2AX foci (arrowed green foci in the merged images in Figure 5-2e, page
125) in BJ, RD or HGPS cells. This indicates that the DSBs induced by genotoxic agents were
different from those formed due to the lamin A defect that disrupts the chromatin-supporting
scaffold.
It is possible that the DNA damage arising in HGPS or RD cells may have a particular
structural signature or readout that is recognized by XPA. Alternatively, XPA could be recruited
to the DSB sites by other cellular factors due to laminopathies. To explore the underlying
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Figure 5-4. Chromatin-mediated XPA-γ-H2AX interaction
(a) γ-H2AX association assay was performed as described in Materials and Methods. HGPS and
BJ cells were treated with the crosslinking agent formaldehyde. BJ cells were treated with 4 µM
camptothecin for 1 hour before the formaldehyde fixation. Immunoprecipitated proteins were
analyzed by Western blotting with indicated antibodies. IP with IgG was used as a negative
control to demonstrate the specificity of γ-H2AX antibody. (b) Co-immunoprecipitation was
performed with nuclease treatment. The nuclear extracts (Input) and precipitated proteins were
analyzed by immunoblotting with indicated antibodies. IP with RPA32 antibody was carried out
in parallel, which served as a positive control demonstrating that the Co-IP conditions used
herein preserved protein-protein interactions.
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Figure 5-5. Laminopathy-induced DSBs are unrepairable
(a) Cells were treated with 4 µM CPT and then harvested at the indicated times for
immunofluorescence analysis. The γ-H2AX foci that did not colocalize with XPA were CPTinduced γ-foci. (b) Focus counting was performed by two blinded observers who randomly chose
50 cells for each experiment. The number of foci was plotted against time post treatment with
CPT.
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mechanism by which XPA is localized to the DSB sites, the association of XPA with γ-H2AX in
HGPS cells was examined using co-immunoprecipitation assay and a modified ChIP (chromatin
immunoprecipitation) assay. In the modified ChIP assay, cells were first treated with
formaldehyde to crosslink protein-DNA and protein-protein complexes. After shearing the
chromatin into 200-1500-bp fragments, the crosslinked chromatin-associated γ-H2AX in cell
extracts was immunoprecipitated with anti-γ-H2AX antibody, followed by reversal of the crosslinking. As shown in Figure 5-4a (page 128), Western blot analysis of the immunoprecipitates
indicated that XPA was associated with γ-H2AX either through direct interaction or mediated by
DNA or other proteins. By contrast, no association between γ-H2AX and XPA was observed for
BJ cells treated with CPT. To determine whether there was a direct interaction between γ-H2AX
and XPA, co-immunoprecipitation (Co-IP) was performed after nuclease treatment using a
Nuclear Complex Co-IP kit (Active Motif, CA). As shown in Figure 5-4b (page 128), the
nuclease digestion of DNA resulted in the loss of XPA-γ-H2AX association, suggesting that their
association in these progeria cells was mediated by chromatin. As a positive control, XPA was
efficiently co-immunoprecipitated with RPA (Figure 5-4b, page 128).

Persistence of XPA-Localized DSBs
To confirm the accumulated XPA-localized DSBs in the patient cells are resistant to
repair, we compared their repair rate to that of CPT-induced DSBs. As shown in Figure 5-5a
(page 129), the XPA-γ-H2AX colocalized foci remained unrepaired in HGPS and RD cells 24
hrs after CTP treatment. By contrast, the number of CPT-induced γ-H2AX foci (not colocalized
with XPA foci) was significantly reduced in the progeroid or BJ cells, although repair in the
patient cells occurred at much slower rates. Further quantitative analysis of the DSB repair as the
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function of time confirmed the results (Figure 5-5b, page 129), supporting that the XPAlocalized DSBs in the patient cells are resistant to repair.

Effects of XPA Knockdown on DSB Repair in HGPS Cells
The appearance of XPA at unrepairable DSB sites may suggest a physiological role of
XPA in the accumulation and persistence of DSBs in progeroid cells. To test this notion, XPA
was knocked down in HGPS cells using XPA-specific siRNA (Figure 5-6a, page 132), followed
by examination for the knockdown effects on accumulation of γ-H2AX in these cells using
Western blotting. As shown in Figure 5-6a (page 132), XPA knockdown consistently resulted in
37-45% reduction of γ-H2AX formation in HGPS cells as compared to that of GFP siRNA
transfected HGPS cells. However, XPA knockdown had no effect on the formation of CPTinduced γ-H2AX in BJ cells (Figure 5-6a, page 132). These results were also confirmed by the
method of immunofluorescence. The number of γ-H2AX foci was significantly decreased after
XPA knockdown (from 9.6+1.6 to 5.5+1.1 foci per cell in HGPS fibroblasts, P = 0.03; from
14.4+2.5 to 8.0+2.1 foci per cell in RD fibroblasts, P = 0.03) (Figure 5-6b, page 132), while XPA
knockdown had no effect on the formation of CPT-induced γ-H2AX foci in BJ cells (Figure 56b, page 132). More direct evidence came from the comet assay of single cell electrophoresis
that also showed significant reduction in DNA double-strand breaks in HGPS cells with XPA
knockdown as compared with the control HGPS cells transfected with GFP-siRNA (Figure 5-6c,
page 132). These results strongly support that XPA may inhibit DSB repair in HGPS and XPA
knockdown by siRNA can partially restore the repair.
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Figure 5-6. DSB repair in HGPS cells with XPA knockdown by RNAi
(a) Knockdown of XPA reduces DSB accumulation. For the knockdown of XPA by RNAi, the
cells were transfected with XPA siRNA (Santa Cruz), or GFP siRNA as a control, using
TransIT-TKO transfection reagent (Mirus) following manufacture’s instruction. Western blotting
was performed to analyze the knockdown efficiency 96 hours after transfection. XPA was shown
as a known doublet of bands plus a weak third band due to phosphorylation siRNA (Wu et al.,
2006). The amount of γ-H2AX was quantified against β-actin, the loading control, by
densitometry. Standard deviations was generated from three independent experiments. The
symbol * indicates P<0.05. (b) Number of γ-H2AX foci in the XPA-siRNA or GFP-siRNA
transfected cells. The symbol * indicates P< 0.05. (c) Comet assays were carried out with XPAsiRNA or GFP-siRNA transfected BJ cells and HGPS cells as described in Materials and
Methods. DNA damage was quantified and expressed as the percentage of DNA in tail.

Discussion
Recent studies have shown that DSBs typically accumulated in HGPS cells and RD cells
and the resulted genome instability might contribute to premature aging (Liu et al., 2005; Manju
et al., 2006; Varela et al., 2005). The accumulation is likely due to the deficiency in DNA repair
in these progeria cells. In the effort to address the important question of why and how DNA
repair is compromised in HGPS and RD cells that appear to have intact DNA repair proteins, we
found that DSB repair proteins Rad51 and Rad50 were absent at the laminopathy-related DNA
damage sites, at least partially contributing to the deficiency of DSB repair in the patient cells.
The absence of Rad50 and Rad51 at DSBs was surprisingly concurrent with the formation of a
significant amount of NER protein XPA foci and the localization of XPA to the unrepairable
DSBs. These uncharacteristic XPA focus formation and localization occurred exclusively in
progeria cells but not in normal fibroblasts. It is possible that the localization of XPA to the
laminopathy-induced DSB sites may deny accessibility of the damage sites to DSB-repair
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factors, thus inhibiting DNA repair. If this is the case, removal of XPA should reduce the
resistance to repair. Indeed, RNAi knockdown of XPA in HGPS cells restored DSB repair by a
significant factor. Consistently, a portion of Rad51 foci was re-localized to γ-H2AX foci after
XPA knockdown as shown in Figure 5-7. However, a large amount of Rad51 remains in
aggregation in HGPS cells, which explains why only partial recovery of DNA repair capacity has
been observed by XPA knockdown. These results suggest that XPA is at least partially
responsible for the DSB repair deficiency in the patient cells.

Figure 5-7. The localization of Rad51 foci and γ-H2AX foci in HGPS cells with or without XPA
knockdown.

Although it has been well documented that XPA is involved in recognition of DNA bulky
lesions in NER, it has no role in DSB repair. Our results from the modified ChIP and coimmunoprecipitation assays (Figure 5-4, page 128) indicated that the association of XPA with γH2AX appeared to be mediated by chromatin. It is possible that disruption of the chromatinsupporting scaffolds formed with nuclear lamins in HGPS and RD cells may produce broken
chromosomes with unique DNA structures recognized by XPA. In support of this notion, we
recently identified a novel activity of XPA for recognition of double-strand/single-strand DNA
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(ds-ssDNA) junctions with 3’- and/or 5’-ssDNA overhangs (unpublished data). The binding
affinity of XPA for these sites is between one and two orders of magnitude higher than its ability
to bind to damaged DNA. This type of DNA structures form as intermediates during some DNA
metabolic pathways including replication and DSB repair. In addition, a recent study
demonstrated that XPA, but not NER-mediated damage processing, is required for UV-induced
S-phase ATR checkpoint activation (Bomgarden et al., 2006) that is replication-dependent.
Interestingly, DSBs could result from replication fork stalling and collapse. In the cases of HGPS
and RD, more details of the uncharacteristic XPA-DNA binding in the progeria cells need to be
defined in the future.
Findings presented in this study serve as the first step towards uncovering the underlying
mechanism of DSB accumulation in premature aging HGPS and RD cells. Our results suggest a
potential pathological role of XPA in development of human progeria diseases in contrast to its
indispensable role in NER to counter NER-deficient diseases. This understanding also provides a
potential strategy for alleviating laminopathy-related progeria syndromes by interfering with
XPA function. In addition, recent studies showed that inhibiting farnesylation of progerin or
prelamin A with farnesyltransferase inhibitors (FTIs) in RD and HGPS fibroblasts could reverse
the aberrant nuclear morphology caused by deficiency in lamin A maturation (Capell et al., 2005;
Glynn and Glover, 2005; Mallampalli et al., 2005; Toth et al., 2005). The inhibition also showed
amelioration of the disease in a mouse model of progeria (Fong et al., 2006). However, we
recently found that FTI treatment could not reduce the accumulated DSBs in both HGPS and RD
cells (Chapter 4). This suggests that DNA damage accumulation and misshapen nuclei are
probably two independent phenotypes caused by lamin A dysfunction in progeria. Thus,
elimination of DNA damage accumulation and improvement of nuclear morphology would be
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potential goals in development of an effective strategy for treatment of progeroid syndromes.
Finally, DNA damage accumulation is believed to be one of the major causes to cellular
senescence and normal aging (d'Adda di Fagagna et al., 2003; Gorbunova and Seluanov, 2005;
Kirkwood, 2005; Lees-Miller, 2005; Lombard et al., 2005; Misteli and Scaffidi, 2005; von
Zglinicki et al., 2005) and the similar unrepairability of DSBs has been reported in senescing
human cells (Sedelnikova et al., 2004). Importantly, lamin A-dependent nuclear defects were
recently found in normal human aging (Scaffidi and Misteli, 2006). Thus, it is of great interest to
determine if XPA plays a role in these processes.
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CHAPTER 6

SUMMARY AND CONCLUSIONS

The maintenance of genomic integrity is a fundamental requirement for cells and
organisms to survive from generation to generation. To contend with both internal and external
insults to the genome, cells have evolved many pathways. These include DNA repair for
removing DNA damage and DNA damage checkpoints for arresting cell cycle progression so as
to allow sufficient time for repair, thus preventing the conversion of DNA lesions to inheritable
mutations. An important player in this complex pathway network is RPA, whose extensive
involvement in DNA metabolism is mediated by its interactions with ssDNA and numerous
proteins engaged in cellular processes. RPA has been extensively studied for nearly 20 years.
However, the exact role of RPA in DNA damage recognition in NER is still unclear. The present
study shows that RPA has a lower binding affinity for damaged ssDNA than for non-damaged
ssDNA, and there was a lack of substantial direct contacts between RPA residues and the lesion
itself. This result indicates that RPA has no direct recognition power for DNA damage. This is in
line with a recent model suggesting that GGR subpathway of NER utilizes XPC-hHR23B as the
initial factor for detecting DNA damage, whereas XPA-RPA functions in verifying the presence
of the DNA lesion (Evans et al., 1997; Missura et al., 2001; Sugasawa et al., 1998; Thoma and
Vasquez, 2003). But how the DNA lesions are verified remains to be elucidated. Our results
would also help answer how the recognition complexes spatially arrange on the adducted DNA.
Because of higher affinity for undamaged ssDNA, RPA may bind to the undamaged single
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strand of the DNA duplex induced by lesions and leave the damaged strand for incision by
endonucleases. The exact spatial arrangement of the repair factors needs further investigation.
RPA hyperphosphorylation has recently become an interestedly studied area (Binz et al.,
2004; Block et al., 2004; Iftode et al., 1999; Liu and Weaver, 1993; Zernik-Kobak et al., 1997;
Zou et al., 2006). We compared the structural characteristics of full-length native and
hyperphosphorylated RPAs using mass spectrometric protein footprinting, fluorescence
spectroscopy, and limited proteolysis (Liu et al., 2005b). Our data showed that upon
hyperphosphorylation of RPA32N, RPA undergoes a conformational change involving the
single-stranded DNA binding cleft of DBD-B. We propose that an interdomain interaction
occurs between the hyp-RPA32N and DBD-B. Further study showed that a synthesized peptide
(aa 11-37 of RPA32) containing phosphorylated Thr-21, Ser-23, and Ser-33, which mimicks
hyp-RPA32N, can bind to RPA and quench the tryptophan fluorescence of Trp-361 in DBD-B.
Moreover, the equilibrium dissociation constant (Kd,obs) for the binding was calculated to be 973
± 101 nM (unpublished data). These data strongly suggest that hyp-RPA32N could affect RPADNA and RPA-protein interactions (with dissociation constants on the order of 10-7 M) by
competitively binding to DBD-B.
The proposed competitive binding model may provide a regulatory mechanism for the
modulation of RPA in DNA metabolic pathways. Bochkareva et al. (Bochkareva et al., 2005)
suggested that ssDNA may structurally compete with p53 for binding to the OB fold of RPA70N
based on a NMR study, which explains why p53-RPA complex formation is affected by the
presence of ssDNA. The acidic N-terminal peptide of Rad51 and ssDNA may compete for the
binding to the OB fold of RPA70A (Stauffer and Chazin, 2004a). The competition for the
multiple binding sites of RPA by DNA and many proteins may contribute to the ordered hand-
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off of DNA from protein to protein in DNA metabolism and switch RPA between pathways
(Stauffer and Chazin, 2004b). The highly acidic free hyp-RPA32N, if not bound by other factors,
may also affect RPA-protein interactions by interfering with the function of acidic RPA32C,
which is a protein-protein interacting domain. A clear direction for future study is the
identification of protein factors that specifically interact with phosphorylated RPA or hypRPA32N. Because of the competitive mechanism for switching between pathways, in vivo
experiments are needed to reveal the overall role of RPA phosphoryaltion in DNA metabolism.
Cellular accumulation of DNA damage has been widely implicated in cellular
senescence, aging, and premature aging. In Hutchinson-Gilford progeria syndrome (HGPS) and
restrictive dermopathy (RD), premature aging is caused by defective maturation of nuclear
structural protein lamin A and linked to accumulation of DNA DSBs. The perplexity for these
laminopathies is that the identified disease-causing genes seem to have no direct relation to the
disease phenotype. In Chapter 4, we showed evidence that in HGPS and RD fibroblasts, DNA
damage checkpoints are persistently activated and the recruitment of DSB repair factors Rad50
and Rad51 to the laminopathy-related DSB sites was impaired. Strikingly, XPA, a unique NER
protein, formed foci and colocalized with the unrepairable DSBs in the patient cells. The data
clearly demonstrated that lamin A dysfunction resulted in genomic instability. This observation
is in agreement with the fact that one of the functions of the lamins is to tether the nuclear
envelope to chromatin. Previous studies also showed that the nuclear lamins play major roles in
chromatin organization, DNA replication and RNA polymerase II-dependent gene expression
(Burke and Ellenberg, 2002; Burke and Stewart, 2002; Gruenbaum et al., 2005; Taddei et al.,
2004). It is possible that disruption of the chromatin-supporting scaffolds formed with nuclear
lamins in HGPS and RD cells may produce broken chromosomes with unique DNA structures
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recognized by XPA. The most significant findings of the present study are that inactivation of
checkpoint kinases ATM and ATR in these patient cells can partially overcome their early
replication arrest, and RNAi knockdown of XPA in HGPS cells significantly restored DSB
repair. This provides a potential strategy for treatment of these devastating premature aging
diseases. More experiments are needed to examine the effects of kinase inactivation and/or XPA
knockdown on the senescence of the patient cells. The generation and analysis of XPA-/Zmpste24-/- mice could provide more information for the development of treatment strategy.
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APPENDIX
ABBREVIATIONS
6-4PP, pyrimidine (6-4) pyrimidone photoproduct
aa, amino acid
AAF, N-acetyl-2-acetylaminofluorene
AF, aminofluorene
AP, 1-aminopyrene
ATM, ataxia telangiectasia mutated
ATR, ATM- and Rad3-related
BER, base excision repair
BPDE, benzo[α]pyrene diol epoxide
Cdk, cyclin-dependent kinase
ChIP, chromatin immunoprecipitation
Chk1, check point kinase 1
Chk2, check point kinase 2
CIP, calf intestinal phosphatase
CPD, cyclobutane pyrimidine dimer CS, Cockayne Syndrome
CPT, camptothecin
DAPI, 4',6-diamidino-2-phenylindole
DBD, DNA binding domain
DMEM, Dulbecco's modified Eagle medium
DNA-PK, DNA-dependent protein kinase
DSB, DNA double-strand break
dsDNA, double-stranded DNA
DTT, Dithiothreitol
EDTA, Ethylenediamine Tetraacetic acid
EMEM, Eagles minimum essential medium
ERCC1, excision-repair cross-complementing group 1
FPLC, Fast protein, peptide and polynucleodide liquid chromatography
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FTI, farnesyltransferase inhibitor
GFP, Green fluorescent protein
GGR, global genomic repair
HEPES, N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
HGPS, Hutchinson-Gilford progeria syndrome
HPG, p-hydroxyphenylglyoxal
HR, homologous recombination
hyp-RPA, hyperphosphorylated RPA
hyp-RPA32N, hyperphosphorylated RPA32 N-terminus
IF, immunofluorescence
Kd,obs, equilibrium dissociation constant
LMA, low melting point agarose
MALDI-TOF, matrix-assisted laser desorption time of flight
MEF, mouse embryonic fibroblasts
MMR, mismatch repair
MRN complex, Mre11/Rad50/Nbs1 complex
MS, mass spectrometry
NER, nucleotide excision repair
NHEJ, nonhomologous end-joining
NHS-biotin, N-hydroxysuccinimidobiotin
NMA, normal melting point agarose
NMR, Nuclear Magnetic Resonance
OB-fold, oligosaccharide/oligonucleotides binding fold
PCNA, proliferating cell nuclear antigen
PI, Isoelectric point
PIKK, phosphoinositide 3-kinase-like kinase
PVDF, polyvinylidene difluoride
Q-TOF, quadrupole-time of flight
RD, restrictive dermopathy
RFC, replication factor C
RNAi, RNA interference
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RPA, replication protein A
RPA32C, RPA32 C-terminus
RPA32N, RPA32 N-terminus
SDS-PAGE, Sodium Dodecyl Sulfate- Polyacrylamide Gel Electrophoresis
siRNA, small interfering RNA
SSB, single-stranded DNA binding
ssDNA, single-stranded DNA
SV40, simian virus 40
TCA, trichloroacetic acid
TCR, transcription coupled repair
TFIIH, transcription factor II H
TTD, trichothiodystrophy
UV, ultraviolet
XP, xeroderma pigmentosum
XPA, XPB etc., xeroderma pigmentosum group A, B etc.
XPC-hHR23B, xeroderma pigmentosum protein C-human homolog of RAD23B
XRCC4, x-ray repair cross-complementing protein 4
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